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Chapter 1. Introduction 
Porcine reproductive and respiratory syndrome (PRRS) is a disease that is 
characterized by reproductive failure in gestating and pregnant pigs and respiratory disease in 
growing pigs. PRRS is currently the most important disease in the swine industry. Annual 
losses incurred by the swine industry as a result of PRRS related illnesses have been 
estimated to range from approximately $560 million 86 to $760 million 52. PRRS has 
challenged and continues to challenge producers and veterinarians in the swine production 
industry and has had a significant impact on swine production and health management. 
Current modified live vaccines are ineffective at providing protection from 
heterologous PRRS virus (PRRSV) strains and have been implicated in causing disease 
themselves 5 59 63 66 75 91 92 116 131 . Killed vaccines, while no longer commercially available in 
the United States, were also unable to prevent infection and disease 73 88 90 117. The humoral 
and cell mediated immune response to PRRSV infection is unusually delayed. Neutralizing 
antibodies to PRRSV do not appear until approximately four weeks post infection and the 
cell mediated immune response is variable with its role in the clearance of virus still being 
investigated 6 7 68 . Passive transfer of concentrated serum antibody containing neutralizing 
antibody has been demonstrated to protect pregnant sows from PRRSV induced abortion and 
confer sterilizing immunity to the piglets and prevent viremia and persistent infection in 
young pigs 67 93 . 
The major neutralizing epitope on the PRRSV is present on an envelope glycoprotein 
(GP) termed GP5 41 95 98 102 128. Other neutralizing epitopes have been found on the envelope 
glycoprotein GP4 and the matrix protein 85 123 138 140. Recent work has demonstrated the 
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matrix protein and GP5 heterodimer may play an important role in generating a neutralizing 
immune response 51 . The major neutralizing epitope of GP5 has been demonstrated to be 
well conserved and present on both North American and European PRRSV strains 95 99 102. 
Monoclonal antibodies against the GP5 epitope of the murine lactate dehydrogenase-
elevating virus (LDV) have been shown to neutralize both LDV and PRRSV in vitro 102. The 
GP5 neutralizing epitope of LDV exhibits a similar amino acid homology to the GP5 epitope 
of PRRSV 99. Additionally, asparagine (N) linked glycosylation sites (N-glycans) present on 
the GP5 ectodomain of LDV have been demonstrated to suppress the immunogenicity of the 
neutralizing epitope 100. N-glycans have been identified on the PRRSV envelope protein 
GP5 and it has been proposed that the glycosylation sites in the region of the PRRSV GP5 
neutralizing epitope provide steric or kinetic hindrance resulting in suppressed 
. . . f h 1. . . 35 100 102 1mmunogemc1ty o t e neutra 1zmg ep1tope . 
Live and modified live PRRS virus vaccines have been shown to provide better 
protection than killed vaccines; however, use of live PRRSV carries the risks of potential 
recombination with field strains and reversion to virulence 92 116 145 . While considerable time 
and resources are being invested in the development of novel live or modified live vaccines, 
second generation killed PRRSV vaccines would better serve the industry in controlling this 
disease. An effective killed PRRSV vaccine would lack the risks associated with live virus, 
could be used in PRRS negative herds, and could potentially be compatible with differential 
diagnostic tests, aiding regional and national eradication. Killed subunit vaccines have been 
utilized for protection from disease associated with the Pseudorabies virus (PRV) 58. 
Inactivated subunit PRV vaccines have been demonstrated to stimulate an immune response 
and provide protection equal to or better than modified live PRV vaccines 40 147. Similar 
3 
methods used in the preparation of subunit PRV vaccines 55 105 have been evaluated in this 
research for the preparation of inactivated PRRSV vaccines. Accordingly, the focus of this 
research was to stimulate a neutralizing and heterologous immune response and evaluate 
protection from infection and clinical disease using killed PRRSV vaccines enzymatically 
treated to remove GP5 N-glycans or killed vaccines derived from natural PRRSV mutants 
possessing fewer GP5 N-glycans. 
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Chapter 2: Literature Review 
Introduction to Porcine Reproductive and Respiratory Syndrome 
Porcine reproductive and respiratory syndrome (PRRS) emerged as a new disease in 
swine in the late 1980s. Decreased performance and mortality was associated with anorexia 
and reproductive failure in the breeding herd and anorexia and respiratory disease in growing 
pigs on farms across the United States. Differential diagnoses included pseudorabies virus, 
parvovirus, porcine enterovirus, porcine cytomegalovirus, encephalomyocarditis virus, 
hemagglutinating encephalomyelitis virus, swine influenza virus, Leptospira bratislava and 
Chlamydia 56. At that time, the name for the disease and its etiologic agent had yet to be 
determined and many variations existed. The more popular names given to the disease in 
Europe included "porcine epidemic abortion and respiratory syndrome," "porcine 
reproductive and respiratory syndrome," and "blue eared pig disease." In the United States 
common names for the disease included "mystery swine disease (MSD)" and "swine 
infertility and respiratory syndrome (SIRS) 146." 
Porcine reproductive and respiratory syndrome virus (PRRSV) was first isolated from 
clinically affected pigs in the Netherlands. The virus was isolated using porcine alveolar 
macrophages and was designated Lelystad virus 130. Koch's postulates were subsequently 
fulfilled using the Lelystad virus to produce reproductive disease in pregnant sows 118. 
Shortly after the Lelystad virus was isolated in Europe, PRRSV was isolated in the United 
States. The virus, ATCC VR 2332, was provisionally termed swine infertility and respiratory 
syndrome (SIRS) virus and was used to fulfill Koch's postulates by producing respiratory 
disease in gnotobiotic piglets 31 . It was not until after the International Symposium on Swine 
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Infertility and Respiratory Syndrome in St. Paul, MN in early 1992 that the name porcine 
reproductive and respiratory syndrome became widely accepted 146. 
Porcine reproductive and respiratory syndrome virus belongs to the order Nidovirales, 
"' ·1 A · . "d d Art . . 19 32 101 0 h A . . . 1 d . 1am1 y rterzvzn ae, an genus env1rus . t er rtenv1ruses me u e equme 
arteritis virus (EA V), lactose dehydrogenase-elevating virus (LDV) of mice and simian 
hemorrhagic fever virus (SHFV) 101 . Porcine reproductive and respiratory syndrome virus is 
----
a polyadenylated, single stranded, positive sense RNA virus. The PRRSV genome is 
approximately 15 kb in size, comprising 9 overlapping open reading frames (ORF); ORFla, 
ORFlb, ORF 2a, ORF2b, ORF3 to ORF 7. Open reading frames la and lb are closest to the 
5' end of the viral genome and make up approximately 80% of the genome, while ORFs 2 to 
7 are at the 3' end of the genome 79• Open reading frame la and ORF lb encode RNA-
dependent RNA polymerase, ORF2a encodes for a glycosylated protein designated 
glycoprotein 2 (GP2), ORF2b encodes for a protein designated 2b, ORFs 3 to 5 encode for 
glycosylated proteins designated glycoprotein 3 (GP3), glycoprotein 4 (GP4), glycoprotein 5 
(GP5), respectively, ORF 6 encodes for matrix (M) protein and ORF7 encodes the 
1 "d (N) . 80 81 124 134 Gl . 5 M N d 2b . . h nuc eocaps1 protem . ycoprotem , , an protem comprise t e 
major structural protein of the virion while GP2, GP3 and GP4 are minor components 134. 
Disease and Diagnosis 
Clinical signs associated with PRRS vary from herd to herd depending on the type of 
production system, the immune status of susceptible animals, dose of virus at exposure, the 
strain of virus and prevalence of secondary infectious agents 45 . Field observations of 
clinical signs are often complicated by coinfections with other bacteria and viruses, however, 
many of the clinical signs associated with PRRS have been reproduced experimentally in 
6 
swine 24 109. In the initial stages of disease the most commonly observed clinical signs 
include lethargy, anorexia, depression and pyrexia. Transient cyanosis of the snout, ears, 
abdomen, vulva and tail can also be observed during the initial stages of disease, although 
more commonly reported in Europe. Signs of respiratory disease involving tachypnea and 
dyspnea (thumping) are observed with greater frequency in younger animals 24 25 . Neonatal 
pigs may also display periocular edema, conjunctivitis, cutaneous erythema, diarrhea, 
shaking, rough hair coat, post-injection bleeding and CNS signs 109. Abortions in sows that 
are between 21 and 109 days of gestation and sow deaths may also be observed. 
Infrequently, CNS signs and vomiting may occur 9 25 . During the next 8 to 12 weeks, late 
term abortions between 109 and 113 days of gestation, increased numbers of stillborn and 
mummified piglets and dramatically increased preweaning mortality is s~enjn the breeding 
herd and can be attributed to transplacental infection. Sows will have delayed returns to 
estrus and the conception rate will be decreased resulting in a decrease in herd reproductive 
performance 9 25 . Boars may be lethargic, anorexic and may display signs of respiratory 
disease. Additionally, the boars may have decreased libido and sperm quality may be 
decreased 9• During this stage of disease the primary clinical signs observed in growing pigs 
are tachypnea and dyspnea 25 . These signs are often exacerbated by secondary infections by 
bacteria and viruses such as Pasteurella multocida, Streptococcus suis, Actinobacillus 
pleuropneumoniae, Haemophilus parasuis, Mycoplasma hyopneumoniae, Salmonella 
choleraesuis, swine influenza virus and porcine circovirus 9 25 38 44 112 115 119 126 133 . Porcine 
reproductive and respiratory syndrome coupled with secondary infections results in increased 
mortality and decreased growth of growing pigs 25 . After the acute stages of an outbreak, 
reproductive performance parameters begin to return to near normal levels, and depending on 
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the management system may return to normal. Endemic or chronic PRRS may be observed 
in the breeding herd with the introduction of naYve replacement gilts and boars. Small 
population of susceptible animals may allow for periodic small outbreaks within the herd. 
The PRRSV may persist in the nursery/finisher environments when younger naYve animals 
are commingled with older infected animal or when persistently infected animals are present 
within a group 9 25. 
The pathogenesis of PRRS has been studied using gnotobiotic, cesareans derived, 
colostrum deprived (CD/CD) piglets and in challenge models involving pregnant swine. 
Pregnant sow challenge models have demonstrated that piglets can be born alive, alive and 
weak, stillborn or mummified. Gross and microscopic lesion may not always be present in 
sows and fetuses 13 24 61 . In challenge studies in which sows were oronasally exposed to 
PRRSV around 90 days of gestation, varying degrees of endometritis and myometritis were 
observed. Transplacental infection resulted in litters with both normal and stillborn fetuses 
and fetuses in varying stages of autolysis 24 61 . Gross lesions were present in the umbilical 
cord of some fetuses varying from 1-2 cm to full length hemorrhagic regions. Edema was 
present around the kidneys, spleen and spiral colon and abdominal and thoracic effusion was 
observed. Microscopically, the lesions in the umbilical cords were characterized as 
necrotizing arteritis with periarterial hemorrhage, and microscopic lung lesions were those of 
interstitial pneumonia, characterized by alveolar septal thickening due to mononuclear cells, 
hypertrophy and hyperplasia and mixed alveolar exudate. Fetal mortality is believed to be 
due to hypoxia, exsanguination into the amniotic cavity and/or disruption of the placental 
barrier 61 . Gnotobiotic pigs intranasally infected with PRRSV develop interstitial 
pneumonia, lymphadenopathy, vasculitis, myocarditis and encephalitis. The pigs become 
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viremic within 12 hours of exposure to virus. Microscopic lungs lesions include alveolar 
septa! thickening with macrophage infiltrates, alveolar proteinaceous and karryorrhetic 
debris, alveolar syncytial cells and type 2 pneumocyte hypertrophy. Lymph nodes lesions 
were characterized by germinal center hypertrophy and hyperplasia, lymphocyte necrosis, 
multiple cystic spaces and polykaryocytes within the spaces. Myocardial lesions were 
characterized by perivascular foci of lymphocytes 111 • In 4 week old CD/CD pigs 
intranasally infected with PRRSV, the microscopic pulmonary lesions associated with PRRS 
involved interstitial changes including septa! infiltration with mononuclear cells, type-2 
pneumocyte hypertrophy and hyperplasia and accumulation of necrotic macrophages and 
debris in alveolar spaces. Follicular hypertrophy, hyperplasia and necrosis were observed in 
lymph nodes, the tonsil and the spleen. Macrophages and dendritic cells were the 
predominant cell type infected and the most severe lesions were in the respiratory and 
lymphoid systems implicating them as the likely site ofreplication 45 . Chronological 
imrnunohistochemical staining following intranasal exposure to PRRSV demonstrated that 
the virus preferentially infects monocytes/macrophages and that pulmonary macrophages are 
the primary cells for virus replication. Initial virus entry occurs through nasal epithelial 
macrophages, tonsil macrophages and pulmonary macrophages 110• Gross lesions associated 
with PRRS include interstitial pneumonia characterized by heavy, wet lungs that fail to 
collapse containing multifocal regions of tan-mottled areas with ill-defined borders 45 47. 
Gross lesions are predominantly located in the cranial, middle and accessory lobes and in the 
ventromedial aspect of the caudal lobes 47 . The presence oflung lesions is inconsistent and 
often complicated by lesions due to secondary infections 109• Lymphadenomegally can also 
be observed, particularly in younger animals, with lymph nodes reaching 2 to 10 times the 
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normal size and with some containing cysts. The heart may be enlarged and rounded and 
pericardia! effusion may be present 45 . 
Variation in clinical signs and lesions associated with PRRSV can be attributed to 
differing degrees of virulence among PRRSV isolates. Halbur et al. demonstrated that field 
isolates obtained from different herds had variable levels of pathogenicity. Some strains 
were able to produce severe pneumonia with estimated percentage of gross lung involvement 
ranging from approximately 17% to 64%. While the degree of lymph node enlargement was 
similar among isolates, some isolates were more apt to induce rhinitis, encephalitis or 
myocarditis 45 46 47. Mengeling et al. 78 similarly demonstrated variation in the ability of 
strains of PRRSV to produce reproductive disease. While all strains utilized in this study 
were able to cause transplacental infection, the number of late term dead fetuses varied 
depending on the strain. 
Transmission of virus between pigs via oronasal 48, parenteral 48, semen 43 137 and 
aerosol 14 37 96 122 routes have been evaluated. As few as 10 virions have been demonstrated 
to be sufficient enough to result in infection via intranasal or parenteral routes 141 . The 
infectious dose50 for oral and nasal exposure to PRRSV have been determined to be 105·3 and 
104·0 TCID50/ml respectively, while a parenteral dose of 102·2 TCID50/mL has been 
demonstrated to be 100% infective 48 . Direct contact between experimentally infected and 
uninfected animals has demonstrated that oronasal and parenteral transmission can occur 14 96 
122
• Parenteral transmission between pigs in field settings is likely due to standard practices 
such as tail docking, ear notching, teeth clipping, medicating and normal pig interaction 48 . 
Transmission of virus via artificial insemination with semen collected from acutely infected 
boars has been demonstrated 43 137. Aerosol transmission has been demonstrated to occur 
10 
d. f 1 2 5 14 96 122 H . 1 . . f over 1stances o meter to . meters . owever, expenmenta transm1ss1on o 
PRRSV has not been demonstrated to occur over greater distances of 15 to 30 meters outside 
of a barn,37 96 122 suggesting that long distance aerosol transmission is infrequent. 
Diagnosis of PRRS is made through observation of clinical signs of disease and a 
combination of diagnostic assays. Commonly used serologic assays include enzyme-linked 
immunosorbent assay (ELISA),26 indirect or direct fluorescent antibody tests (IFA or FA) 22 
142
, immunoperoxidase monolayer assay (IPMA) 22 142, serum-virus neutralization (SVN) 85 
and fluorescent focus neutralization (FFN). Diagnostic tests that detect PRRSV in tissues 
include histopathology, direct tissue fluorescent antibody tests and immunohistochemistry 
(IHC) 46. Viral RNA can be detected in a variety of tissue and fluid samples using reverse 
transcriptase-polymerase chain reaction (RT-PCR) 28 120. Reverse transcriptase PCR 
products can used to sequence the amplified genomic information 121 . Virus isolation can 
also be performed from body tissues and fluids 26 30. 
The PRRS ELISA (HerdChek; IDEXX Laboratories Inc., Westbrook, Maine) is the 
most commonly used serologic test for determination of PRRS status in pig populations. The 
PRRS ELISA is an indirect assay that can detect antibodies to nucleocapsid protein from 
both North American and European PRRSV. The assay is highly sensitive, 100%, and 
specific, 99.5%, and is used to determine exposure to PRRSV 26 . Antibodies to nucleocapsid 
protein can be detected between 9 and 13 days, with peak antibody titers occurring between 
30 and 50 days post exposure and lasting for greater than 10 months. Results are reported as 
sample-to-positive (S/P) ratios with values greater than or equal to 0.4 indicating a positive 
test result 30. 
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The IF A for antibody has good specificity, 99.5%, but the sensitivity is unknown and 
is dependent on several factors in the laboratory 30. The timeline for antibody detection with 
IF A is similar to that of the ELISA. An IF A antibody titer of 1: 16 or 1 :20 is considered a 
positive result indicating the presence of PRRS antibody 30. 
The serum-virus neutralization assay measures the ability of serum antibody to 
prevent infection in cell culture. Fluorescent focus neutralization is similar to the SVN assay, 
but is more sensitive and has more accurate endpoints 84 . Neutralizing antibodies are 
produced by the pig at inconsistent intervals after PRRSV exposure, making these assays less 
sensitive and more useful as research tools 23 26 42 68 85 139 142. Neutralizing antibodies may be 
detected for greater than one year post exposure and a neutralizing antibody titer of 1 :4 or 
greater is considered positive 30. The addition of complement, in the form of fresh swine 
serum, to serum neutralizing assays has resulted in detection of neutralizing antibody earlier 
than without the addition 139. Similar observations have been made in equine arteritis virus 
(EA V) neutralizing assays 106 
Reverse transcriptase PCR detects a portion of the PRRSV genome. ORF 7 is the 
most highly conserved genomic region and is often detected 28 . Open reading frame 5, in 
which there is more genomic variation can also be detected and is often sequenced 20 121 . 
Using RT-PCR can lead to a diagnosis of PRRSV infection prior to the development of an 
antibody response resulting in earlier diagnosis 26. Reverse transcriptase PCR has been 
utilized to detect PRRSV RNA in serum and tonsil of infected pigs up to 251 days post 
exposure to virus 132. 
12 
Humoral Immune Response 
The humoral immune response of pigs following infection is characterized by a rapid 
anti-N protein antibody response detected by ELISA and IF A within 7 to 21 days post 
infection 10 23 27 36 45 64 69 142. Anti-N protein antibody has been demonstrated to be non-
1. . d . 16 74 142 Th 1· . . b d d neutra 1zmg an non-protective . e neutra 1zmg immune response can e etecte 
by SVN or FFN beginning as early as 9 days to 14 days post infection 23 42 142 and as late as 
32 to 70 days post infection 34 60 74 82 139. The humoral immune response induced by 
d"fi d 1· . C 11 . ·1 b d . l . C • 71 82 92 mo 1 1e 1ve vaccmes 10 ows a s1m1 ar pattern as o serve m natura m1ect10n . 
Nucleocapsid antibodies are detected between 14 and 28 days post vaccination and 
neutralizing antibodies are detectable by six to eight weeks post vaccination 21 71 . Inactivated 
vaccines fail to induce a humoral immune response as demonstrated by a lack of detectable N 
protein antibodies and neutralizing antibodies 74 89. However, pigs infected with PRRSV or 
vaccinated with a modified live vaccine that subsequently received an inactivated vaccine 
have been shown to develop higher neutralizing antibody titers than pigs not receiving 
inactivated vaccine 89. 
Specific viral proteins associated with neutralizing immune response have been 
investigated. The membrane protein GP5 has been associated with inducing the greatest 
neutralizing antibody response 95 102 128. Neutralizing epitopes on GP4 and M protein have 
also been demonstrated, although the importance of their role in the clearance of virus is not 
clear 16 85 123 138_ 
The primary neutralizing epitope on the PRRSV has been determined to be located on 
GP5 by using serum from pigs infected with PRRSV strain VR 2332 and an indirect peptide 
ELISA 102. The results indicated that the neutralizing epitope was located in the middle of 
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the GP5 ectodomain between amino acids 36 and 52. Additional work indicated that two 
epitopes are present in the middle of the GP5 ectodomain 95 . The first epitope, epitope A, 
was determined to be located at amino acids 27 to 30 and was shown to elicit an intense non-
neutralizing antibody response. The second epitope, epitope B, was determined to be located 
in the region of amino acids 3 7 to 45 and was shown to be the target of neutralizing 
antibodies. These results suggested that epitope A could be a decoy epitope and possibly 
explain the delayed onset of the neutralizing antibody response. Similar observations of a 
decoy epitope have been made with the human immunodeficiency virus (HIV) 29. 
Passive immunization studies have demonstrated that neutralizing antibody is capable 
of preventing PRRS related disease 67 93 . Antibodies from hyperimmunized pigs, prepared 
by repeated PRRSV inoculation over a seven to 14 month period, have been used to 
passively immunize gilts 93• Gilts passively received antibody and three days later, at 90 
days of gestation, were challenged with PRRSV. Following passive transfer, gilts had a 
serum neutralizing antibody titer of 1: 16. Passive transfer of hyperimmunized serum 
provided complete protection from reproductive failure. Animals that received the 
hyperimmunized serum had significantly higher percentage of live born pigs, 95%, and live 
pigs at 15 days post farrowing, 95%, than pigs in the control group with 18% live born and 
4% live pigs at 15 days. Additionally, passively immunized pigs did not become viremic and 
transplacental infection of the offspring was prevented. Further studies using the same 
hyperimmunized serum demonstrated that viremia could be prevented and that sterilizing 
immunity could be achieved in young pigs 67. Viremia was prevented in two week old pigs 
that were passively immunized and challenged one day later. Pigs with a serum neutralizing 
antibody titer of 1 :8 following passive immunization were protected from viremia, however 
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PRRSV was detected in the lungs and lymph nodes and transmission of virus to sentinel pigs 
was observed. Pigs with a serum neutralizing titer of 1 :32 were also protected from viremia 
and in three of the six pigs in this treatment group PRRSV could not be detected in the lungs 
or lymph nodes. However, transmission of PRRSV from pigs with neutralizing antibody 
titers of 1 :32 to sentinel pigs did occur. 
Antibodies to PRRSV and specifically, low levels of neutralizing antibodies have 
been associated with antibody-dependent enhancement (ADE) of infection 23 143 144. 
Antibody-dependent enhancement of virus infection is mediated by the binding of virus 
specific IgG and the Fe receptors ofmonocytes or macrophages 17. Evidence of in vivo ADE 
was first demonstrated in fetuses that were inoculated with PRRSV and PRRSV antibodies 
while in utero 23 . Fetuses receiving this inoculation demonstrated higher virus titers than 
fetuses inoculated with PRRSV only. Pigs passively immunized with low levels of 
neutralizing antibody, <1 :4, have been shown to develop a higher and longer lasting viremia 
than pigs that passively received normal swine serum or serum with neutralizing antibody 
titers of>l:8 143 . Further work evaluating ADE has demonstrated that PRRSV strains that 
induce high neutralizing antibody titers are less susceptible to ADE than PRRSV strains that 
induce low levels of neutralizing antibody, indicating that the potential for ADE is strain 
dependent 144. 
Cell Mediated Immunity 
The cell mediated immune (CMI) response developed in response to PRRSV 
infection continues to be characterized. The role of CMI associated with PRRSV was 
initially evaluated by monitoring T-cell responses in vitro using peripheral blood 
mononuclear cells stimulated with viral antigen 7. The T cell response was shown to 
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correspond with the neutralizing antibody response and consisted primarily of CD4+ T cells 7 
82
. Further characterization was performed in vivo using PRRSV infected pigs that were 
inoculated intradermally with inactivated PRRSV 7 82 . Delayed type hypersensitivity 
reactions were observed in these pigs indicating that a CMI response was elicited. 
Interferon-gamma is an activator of macrophages and has been associated with 
protection against viral infection 39. The role of interferon-gamma in PRRSV infection was 
evaluated by incubating porcine monocytes and alveolar macrophages in the presence of 
recombinant porcine interferon-gamma prior to PRRSV infection 8• The recombinant 
interferon-gamma significantly inhibited PRRSV replication and decreased the number of 
activated macrophages capable of supporting PRRSV replication, suggesting that interferon-
gamma may induce an antiviral effect. A study by Rowland et al. 113 found that interferon-
gamma was able to inhibit replication of both wild-type and tissue-culture adapted PRRSV 
isolates. Additionally, the results from this study suggested that interferon-gamma was able 
to suppress PRRSV replication in permissive cells in non-lymphoid tissue, but was unable to 
suppress PRRSV replication in a subpopulation of permissive cells within lymphoid tissue. 
In pigs experimentally inoculated with PRRSV, interferon-gamma secreting cells were not 
detected in peripheral blood mononuclear cells until three weeks after exposure to PRRSV 71 • 
The number of interferon-gamma secreting cells remained at a near steady state for 10 to 12 
weeks post exposure and then began to gradually increase. These results indicated that the 
intensity of the interferon-gamma response during PRRSV infection was prolonged and was 
lower than the interferon-gamma response induced by pseudorabies virus infection. In 
contrast to these findings, a study by Batista et al. 6 demonstrated that interferon-gamma 
secreting cells were present at 14 days post exposure to PRRSV and the intensity peaked 
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between 50 and 70 days post exposure. This chronological difference could be explained by 
either differing challenge strains or the sensitivity of the assays employed to monitor the 
response. 
The ability of modified live vaccines (ML V) to induce interferon-gamma secreting 
cells has been evaluated and was found to be variable and weak 33 114. Interferon-alpha is 
known to promote the differentiation of T cells into cells capable of interferon-gamma 
production 87, furthermore, interleukin-12 (IL-12) can promote the same outcome in 
infections that weakly induce interferon-alpha expression 33 . Infections by PRRSV induce 
low levels of interferon-alpha and low levels ofIL-12 114 125 , contributing to the slow 
development of the CMI response. In an effort to increase the number of interferon-gamma 
secreting cells, the use ofIL-12 or interferon-alpha as vaccine adjuvants has been evaluated 
72 114
• Interferon-gamma adjuvanted ML V enhanced the number of interferon-gamma 
secreting cells, with peak numbers occurring between two and four weeks post vaccination, 
while IL-12 adjuvanted ML V also enhanced the number of interferon-gamma secreting cells 
at a lower level 72• However, when compared to controls, the level ofviremia in animals that 
received either interferon-gamma or IL-12 was not different from levels observed in animals 
receiving only ML V. Viremia in the presence of elevated numbers of interferon-gamma 
secreting cells has been observed in other studies 135, resulting in questions being raised 
about the importance of the interferon-gamma secreting cells in the clearance of PRRSV. 
However, recent work involving the administration ofrecombinant IL-12 demonstrated that 
porcine BAL cells from PRRSV infected and recombinant IL-12 inoculated pigs were able to 
secrete larger amounts of interferon-gamma and that these pigs had a diminished viremic 
peak and increased growth performance 18. Moreover, a field study by Lowe et al. 70 found a 
17 
positive correlation between the reduction of abortions in sows and the level of interferon-
gamma secreting cells present in the peripheral blood. Results from this study suggested that 
increasing the level of cell mediated immunity present within a herd may decrease the level 
of clinical disease. 
PRRS Vaccination 
The use of commercially available and autogenous PRRS vaccines is a controversial 
topic. Ideally a PRRSV ML V vaccine would be able to reduce clinical signs and symptoms 
caused by all wild-type PRRS viruses while not causing disease itself. Additionally, this 
vaccine would be unable to revert to virulence and any mutations made to the vaccine virus 
would be antigenically distinguishable from wild-type viruses so that differential diagnostics 
could be performed to distinguish vaccinated animals from wild-type virus infected pigs 127. 
At the present time a PRRSV ML V vaccine meeting these criteria does not exist. 
Commercial PRRSV ML Vs have been available for the prevention and control of PRRSV 
since 1994. Only one inactivated PRRSV vaccine had been commercially available in the 
United States and at the present time an inactivated commercial product is not available. The 
I~ , ~ :;.::) 
commercial MLV products are Ingelvac ERRS MLV and Ingelvac l(RRS A:Ivand are 
produced by Boehinger Ingelheim Vetmedica Inc., St. Joseph, Missouri. Ingelvac PRRS 
ML V was the first vaccine approved for use and is labeled for use in healthy susceptible 
swine in PRRS virus-positive herds. Ingelvac PRRS ML V is recommended for pigs three-
weeks of age and older to reduce disease associated with PRRS and at 3-4 weeks prior to 
breeding for sows and gilts 12. The parent virus for this vaccine is PRRS strain ATCC VR-
2332. The Ingelvac PRRS ATP was first marketed in 1999 and the parent virus for the 
vaccine is an atypical PRRS virus strain. This vaccine is labeled for use in healthy, 
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susceptible swine 3 weeks of age and older, up to 18 weeks of age in PRRS positive herds as 
an aid in the reduction of symptoms associated with the respiratory form of atypical PRRS 11 • 
Commercial PRRSV modified live vaccines have been shown to provide partial 
protection from reproductive failure, however, protection has only been reliably 
demonstrated in challenge models using homologous challenge PRRSV strains 42 49 so 63 64 . 
Commercial vaccine efficacy trials have demonstrated that modified live vaccines can 
provide protection from reproductive failure. Gorcyca et al 42 indicated that protection from 
reproductive failure could be achieved in pigs that were immunized prior to breeding with 
PRRS ML V and challenged at 90 to 93 days of gestation with PRRSV strain VR 2332 or the 
European Lelystad virus. In the homologous challenge trials, it was demonstrated that PRRS 
ML V could prevent viremia in the sows and the piglets. Furthermore, a significantly higher 
percentage of live/healthy born piglets were seen in the vaccinated groups, 95% and 94%, 
compared to the percentage oflive/healthy born piglets in the control group, 13% and 10%. 
In heterologous challenge trials, a significant increase in the percentage of piglets surviving 
to 28 days was observed in the vaccinate group from one trial and in another trial a 
significant increase in the number of live/healthy piglets was observed in the vaccinate 
group. The results from the homologous and heterologous studies indicated that complete 
protection could be achieved during homologous challenge. However, in one heterologous 
challenge study, virus was recovered from piglets born to 7 of the 28 vaccinated gilts. Thus, 
improved reproductive performance was provided while complete protection against viral 
infection was not. Similar findings were observed in commercial vaccine efficacy trials 
involving the modified live vaccine Prime Pac PRRS 49 50. Homologous and heterologous 
trials were performed using PRRSV strains Neb-1 and 94-2367, respectively. A homologous 
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challenge trial demonstrated that viremia was prevented in both gilts and piglets following 
challenge and that piglet mortality at parturition was significantly lower for the vaccinate 
group. Furthermore, at 7 weeks of age, piglet mortality was significantly lower in pigs 
farrowed from vaccinates, 15%, as compared to non-vaccinates, 24% 49 . A heterologous 
challenge trial demonstrated that viremia was prevented in the gilts following challenge, 
piglet mortality at parturition was significantly lower in the vaccinated group and piglet 
mortality at 14 days was significantly lower for the vaccinated group, 4.9%, compared to 
non-vaccinated group, 90.5%. However, challenge virus was isolated from 4.8% of the 
stillborn and/or live born piglets from the vaccinated group 50 . 
Experimental trials evaluating reproductive protection have indicated that protection 
provided by immunization with ML V or live virus is strain specific, indicating that protection 
from reproductive disease can occur only when challenge occurs with a homologous strain 77 
Lager et al. 64 demonstrated that gilts exposed to virus at day one of gestation and 
subsequently challenged with homologous virus at 90 days of gestation had no evidence of 
transplacental infection, viremia or virus present in tissues at 111 days of gestation. 
Additional studies determined that the duration of homologous immunity in PRRSV infected 
pigs is at least 604 days 65 . 
Heterologous exposure to challenge virus was evaluated in gilts that were inoculated 
with PRRSV strain NADC-8 and challenged with Lelystad virus at 90 days of gestation 63 . 
At 21 days post challenge, five of eight gilts had virus in their bronchio-aveolar lavage 
(BAL) sample and evidence of transplacental infection was present in one gilt. Comparison 
of these findings with results of the homologous challenge group, in which no virus was 
present in gilts and transplacental infection had not occurred, confirmed that complete 
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protection is not achieved in heterologous exposure. Benson et al. 10 also evaluated 
heterologous protection in sows that had been vaccinated with PRRS ML V prior to gestation 
and challenged with PRRSV strain NADC-8 at 90 days of gestation. Protection was 
measured by fetal infection rate and protection was demonstrated only in challenged 
vaccinated groups that received low dose (102 CCID50/ml) viral challenge; suggesting 
protection against clinical disease was contingent on the antigenic similarity between vaccine 
and challenge virus and may be dose dependent. Heterologous protection in breeding age 
pigs was evaluated in pigs that were immunized with a strain of PRRSV and challenged 120 
days later with four strains ranging in ORF5 sequence homology to the vaccine strain of 
3.4% to 16.5%. Pigs in each of the four heterologous virus groups were found to be viremic 
following challenge 5• 
Commercial ML V labels state that the vaccine is not to be used in gestating animals 
and boars. However, the vaccine has been used in extra label manners on some farms. 
Production and vaccination protocols from 14 7 herds were evaluated and it was determined 
that vaccinating sows while gestating results in fewer pigs born alive and weaned than 
vaccinating sows that had already farrowed 34. Sows infected with PRRSV at the beginning 
of gestation are protected from reproductive failure and transplacental infection following 
exposure to homologous PRRSV at 90 days of gestation, sows exposed to PRRSV at 30 days 
of gestation are not; suggesting that sows may clear the virus by 80 days post exposure 64. 
Sows exposed to PRRSV during late term gestation do not provide adequate maternal 
immunity to piglets. Piglets are either infected or become infected from littermates 
indicating more time may be necessary for the sow to develop an immune response capable 
of providing maternal immunity 97• Attenuated vaccines administered prior to gestation 
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provide piglets with some maternal immunity that is able to prevent viremia and clinical 
signs of disease when exposed to a low dose challenge. Piglets that have received passive 
immunity require a challenge dose of 2:103·2 TC!D50 to become viremic indicating that 
passive immunity has protective capabilities 83. 
Vaccination of boars with ML V resulted in a period of vaccine virus shedding in the 
semen. Upon subsequent exposure to homologous virus, boars exhibited minimal to non-
existent shedding of virus in semen and were protected from viremia and respiratory signs 
associated with PRRS; however decreased sperm quality was associated with vaccination and 
challenge 27 . Nielsen et al. 88 found similar findings in boars receiving MLV. Vaccinated 
boars had a decreased level of viremia and duration of shedding following challenge, 
although complete protection was not provided. 
Protection from respiratory disease associated with PRRS afforded by ML V is partial 
or incomplete. Vaccination of 6 week old pigs with attenuated PRRSV strains of either 
American or European origin provided only partial protection to the lungs. The severity of 
gross lung lesions and level of viremia were better when the challenging virus was 
homologous, but still incomplete 59. Vaccination of 2-3 week-old pigs with modified live 
vaccines did not provide protection from gross lung lesions and virus in the lungs after 
simultaneous heterologous and homologous challenge 75 . 
Protection provided by killed PRRS vaccines have been shown to provide minimal 
protection against PRRS virus associated diseases. Moderate success, in terms of 
reproductive failure, using killed vaccine was demonstrated in sows that were vaccinated 
with an inactivated vaccine and then challenged with homologous virus late in gestation. 
Over the course of four experiments, sows vaccinated with an inactivated PRRSV 
22 
preparation had 80% of piglets born alive while challenge control sows had 11 % of piglets 
born alive 104. The most success in using killed PRRS vaccines occurred when live virus was 
already circulating in the herd or after vaccination with a modified live vaccine. Vaccinating 
sows in PRRS positive herds with an inactivated vaccine resulted in a significant decrease in 
the number of stillborn or mummified piglets and a decreased rate of early farrowing. 
However, the number of pigs born alive was not significantly different between vaccinated 
and control animals 108. In a trial involving 17 farms, three vaccinations with a killed PRRS 
vaccine, two doses three weeks apart and one dose at mid-gestation, resulted in a significant 
decrease in the number of early farrowings, stillborn or mummified piglets per litter, 
preweaning mortality, wean to service interval and a significant increase in the number of 
pigs born alive 107. 
Attenuated live vaccines have been shown to replicate in sows 62 and transplacental 
infection has been demonstrated following MLV vaccination in late gestation 77. 
Additionally, transmission of ML V virus, in the absence of transplacental infection, from 
sows vaccinated at 60 or 90 days of gestation has been documented between the sow and her 
suckling piglets 77 . 
The ability of ML V virus to revert to virulence has been demonstrated by analyzing 
ORF5 and ORF7 sequences from field samples obtained in Denmark. Denmark had begun 
vaccinating 3 to 18 week old animals in attempt to limit the spread of PRRS. The vaccine 
was derived from the North American PRRS isolate VR 2332 and not the Lelystad virus that 
was endemic in Europe. Of the 20 isolates sequenced, all 20 had reversion to VR 2332 
sequence at position 13; 18 of 20 had undergone reversion to VR 2332 sequence at position 
151 suggesting that selective pressure results in enhanced replication in vivo 116. Additional 
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evidence of reversion was attained by comparing two PRRSV isolates from farms 
experiencing severe reproductive and respiratory disease to the Inglevac PRRS ML V. One 
of the field strains was demonstrated to share 99.5% ORF5 nucleotide sequence homology to 
Ingelvac PRRS MLV, 98.5% homology to VR 2332 and to be pnuemovirulent suggesting 
that the virus was a virulent derivative of the vaccine virus 92 . 
Recombinant Vaccination 
Vaccine candidates have been developed using infectious cDNA clones of Lelystad 
virus. In one study, three recombinant vaccines were made, one involving a mutation in the 
minor envelope protein GP2, another involving a substitution of M protein with M protein 
from lactate dehydrogenase-elevating virus and the final vaccine involving a deletion to part 
of the nucleocapsid protein. The recombinant vaccines did not cause clinical disease; 
however, all three induced viremia and vaccinated pigs transmitted vaccine virus. Challenge 
studies involving the three vaccines indicated that homologous protection was provided by 
the recombinant involving the M protein; however heterologous protection was not achieved 
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Gene deleted PRRS viruses have been evaluated as potential vaccine candidates. 
Replication deficient mutants were created from cDNA clones by deleting ORF2 and ORF4 
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. The replication deficient mutants were used to immunize 2 week old pigs. Following 
homologous challenge, all treatment groups showed a reduced level of viremia; however, 
macroscopic lung lesions and viral presence within the lungs were found in all treatment 
groups indicating only partial protection. DNA vaccines made with plasmids encoding 
combinations of ORF 5 and 7 and interleukin-2 (IL-2) and interferon-gamma have been 
evaluated 136. Pigs immunized with plasmids possessing ORF7 induced an antibody response 
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earlier than plasmids possessing ORF5, which was expected as ORF7 encodes the 
immunodominant nucleocapsid protein. Gross and microscopic lung lesions as well as the 
number of antigen positive cells were decreased in the DNA vaccinated groups ORF5 with 
IL-2 and ORF5 with interferon-gamma suggesting that the addition of interferon-gamma and 
IL-2 may improve the efficacy of DNA vaccines. Similarly, Barfoed et al. 3 cloned all open 
reading frames from a Danish PRRS isolate into individual DNA vaccines using recombinant 
plasmids. Groups of pigs were vaccinated with recombinant plasmids expressing one of the 
ORFs and subsequently challenged with homologous virus. DNA vaccination of pigs with 
vaccines containing ORF7 resulted in nucleocapsid antibody detection prior to challenge, 
while ORF5 DNA vaccination resulted in the most rapid and highest neutralizing antibody 
response. None of the vaccines, however, were able to prevent or reduce viremia following 
challenge. 
Immunization of pigs using a DNA vaccine with a plasmid expressing the ORF5-
encoding GP5 membrane protein resulted in a neutralizing antibody response, protection 
from extensive macro- and microscopic pulmonary lesions and lessened the viral burden in 
the lungs compared to control animals. Virus persistence and shedding from the respiratory 
tract was not prevented, thus indicating only partial protection 98 . Partial protection was also 
demonstrated using a vaccine in which GP5 and Matrix proteins were expressed in the anti-
tuberculosis vaccine strain Mycobacterium bovis Bacille Calmette-Guerin (BCG). Pigs were 
immunized and given a homologous challenge 60 days later. Three out of five vaccinated 
pigs elicited a weak neutralizing response prior to challenge and at 7 days post challenge. 
Pigs in the vaccinate group also displayed a significantly reduced viremia and lower viral 
levels in bronchial lymph nodes at 7 days post challenge 4. A study by Plana Duran et al. 103 
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was able to demonstrate partial protection from reproductive failure using cloned ORFs 3, 5 
and 7 and inserting them into recombinant baculoviruses. The recombinant baculoviruses 
were used to produce ORF 3, 5 and 7 gene products which were subsequently used to 
vaccinate pregnant sows. The sows were challenged with homologous virus between 70 and 
90 days of gestation. Sows vaccinated with ORF3 gene products had 68.4% of pigs born 
alive and healthy at weaning while 50% of pigs from ORF5 vaccinate sows were born alive 
and healthy. Additionally, piglets from ORF3 or 5 vaccinated sows were seronegative at 
weaning indicating that viral replication had not occurred. 
Recently, a DNA vaccine expressing GP5/M heterodimer elicited higher neutralizing 
antibody titers and a greater enhanced CMI response in the mouse and pig than a DNA 
vaccine expressing GP5 alone 51 . Similarly, the major envelope protein (GL) and matrix 
protein (M) heterodimer of the Arterivirus equine arteritis virus (EA V) has been shown to be 
necessary for the development of neutralizing antibody in mice and horses 1 2. Ribonucleic 
acid replicon particles derived from the Alphavirus Venezuelan equine encephalitis (VEE) 
virus were used as vectors to express GL and M protein of EA V in heterodimer form. The 
resultant GJM heterodimer was able to induce neutralizing antibodies in mice and horses 
and decrease virus shedding and clinical signs in challenged horses. Accordingly, these 
results suggested that the PRRSV GP5/M heterodimer may be important for induction of the 
neutralizing antibody response 51 . 
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Chapter 3. Materials and Methods 
Vaccine Preparation 
Experiment 1 
A virulent abortifacient strain IA 97-7895 of PRRSV was propagated in MARC-145 
cells 57. MARC-145 cells were grown in 75 cm2 flasks using media containing Dulbecco's 
Modified Eagle' s Media (DMEM, Sigma-Aldrich Inc.) with 10% Fetal Bovine Serum (FBS), 
1 % L-glutamine and 0.2 mg/ml gentamicin. Once cells formed a complete monolayer, 
inoculation of PRRSV was performed by adding 5 ml of PRRSV to the flask and allowed to 
attach to cells for 1 hour at 37°C with 5% of CO2• After 1 hour, approximately 20 mls of 
DMEM with 4% FBS was added to the flask. Cells were then incubated at 37°C with 5% 
CO2 until approximately 85% cytopathic effect (CPE) was reached. The flask was removed 
from the incubator and placed in -80°C freezer overnight. The following day, the flask was 
removed and quickly thawed in 37°C water bath and then refrozen at -80°C. On the third 
day, the flask was again placed in 3 7°C water bath until the monolayer cracked, and then was 
thawed at room temperature. The infected cell solution, now detached from the flask, was 
removed from the flask and placed into centrifuge tubes. Virally infected cells were 
centrifuged at 1500 RPM for 15 minutes. Supernatant was removed and saved as infectious 
PRRS virus. The pellets in the centrifuge tubes were washed with DMEM to remove the 
FBS. Again the infected cells were centrifuged at 1500 RPM for 15 minutes and supernatant 
was removed and discarded. The wash step and centrifuge step was repeated twice more for 
a total of 3 wash and centrifuge steps. After discarding the wash, the pellets were 
resuspended in a Trizma/Tricine (TT) buffer with 0.1 % Triton X. The solutions were stirred 
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at 4°C overnight, avoiding bubble formation. After stirring overnight, cell solution was 
centrifuged at 1500 RPM for 15 minutes. Supernatant was removed, centrifuged again for 30 
minutes at 1500 RPM, removed and placed into a new centrifuge tube. Enough TT buffer 
was added to make 12 ml. This solution became the crude viral antigen (CV A). A control 
flask of MARC-145 cells was treated identically to that of CV A, excluding infection with 
PRRS virus, to provide cell culture antigen (CCA). 
Glycoprotein Purification/Isolation 
Immobilized lectin from Lens culinaris (LcH, EyLabs Inc.) was equilibrated in a 20 
ml column in TT Buffer with Triton X. After following EyLabs instructions for 
equilibration, CV A was allowed to flow through the column. The eluted material was used 
as the vaccine CV A/Lectin. A protein assay was set up on column flow-through and eluent 
( eluted with TT buffer with 2.5% Mannose ). The protein concentration was the same in the 
flow-through as the CV A, indicating no binding had occurred between the glycoprotein and 
the lectin. It was decided at that point to enzymatically treat the CV A rather than trying to 
isolate glycosylated protein. 
Enzymatic treatment of CV A 
Enzymatic deglycosylation of the CVA was performed using Fast Protein Liquid 
Chromatography (Pharmacia). Crude viral antigen was dialyzed into a buffer of 0.1 M 
sodium acetate, 0. 15 M sodium chloride, 0.001 M ethylenediaminetetraacetic acid (EDTA), 
pH 4.8 to prepare the CVA for treatment. The PNGase F attached to agarose (Sigma) was 
packed into a column and equilibrated in the sodium acetate buffer. The CVA was added to 
the column and allowed to re-circulate through the column for approximately 2.2 hours, until 
absorbance of the flow-through (wavelength 280) was no longer detectable. This solution 
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became the CV A/Lectin/PNGase F. Neuraminidase was also attached to agarose and packed 
in a column. A separate volume of CV A was treated by the neuraminidase column in the 
same manner as that of the PNGase F column. Crude viral antigen treated with 
neuraminidase, CVA treated with PNGaseF, and CVA treated with both neuraminidase and 
PNGaseF were all assayed for total protein. 
The vaccine preparations were filter sterilized and emulsified in Freund' s Incomplete 
Adjuvant prior to vaccination and injected intramuscularly in the semimembranosus and 
semitendinosis muscles at 1 ml per injection site. One milliliter of viral antigen was 
emulsified in 1 ml of Freund's Incomplete adjuvant using two 5 ml syringes and a sterile 
plastic elbow connector. 
Experiments 2 & 3 
Vaccine preparation in Experiment 2 was perform identically to the Experiment 1 
procedure with the exception of the steps involving lectin. The attempted purification of 
glycosylated protein was left out and CV A was treated enzymatically as previously 
described. Experiment 3 vaccine preparation was identical to the preparation of vaccine in 
Experiment 2. An additional PRRSV strain, SNG, was used to prepare CVA and used as a 
treatment group. 
Total Protein Levels in Vaccines 
Protein concentrations for each inactivated vaccine were determined using the Bio-
Rad RCDC protein assay kit. In Experiment 1, protein levels in the vaccines were as 
follows: Group 1 - 10 ug/ml, Group 2 - 10 ug/ml, Group 3 - 10 ug/ml, Group 4 - 20 ug/ml. 
In Experiment 2, protein levels in the vaccines were as follows: Group 2 - 10 ug/ml, Group 3 
- 10 ug/ml, Group 4 - 10 ug/ml, Group 5 - 20 ug/ml, Group 6 - 30 ug/ml. In Experiment 3, 
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protein levels in the vaccines were as follows: Group 2 - 250 ug/ml, Group 3 - 250 ug/ml, 
Group 4 - 250 ug/ml, Group 5 - 250 ug/ml, Group 6 - undetermined protein concentration, 
given at manufacturer' s recommended dose. 
Experimental Design 
Three experiments were conducted using killed PRRS vaccines; Experiment 1, 
Experiment 2 and Experiment 3. 
Experiment 1 
Experiment 1 involved four groups of six pigs. Three week old pigs were randomly 
assigned to treatment groups, blocking for weight and sex. Table 3.1 displays the design for 
Experiment 1. 
Table 3.1: Experiment 1 Design. 
Table 1: Experiment 1 Design 
Group Number Treatment 
1 CCA 
2 CVA 
3 CVNLectin 
4 CV NLectin/PN GaseF 
Number of Pigs 
6 
6 
6 
6 
Group 1 consisted of positive control pigs treated with crude cellular antigen (CCA), Group 2 
treated with crude viral antigen (CVA), Group 3 treated with crude viral antigen bound to 
lectin without enzymatic treatment (CV NLectin), Group 4 crude viral antigen bound to 
lectin and enzymatically treated with PNGase F (CV NLectin/PNGaseF). Crude viral 
antigen was prepared from PRRS strain IA 97-7895. Pigs in each group received three 
vaccinations with respective vaccines at three week intervals. Blood was collected at three 
week intervals. At 56 days after the first vaccination, all pigs were challenged 
intramuscularly (IM) with two milliliters of 6 X 106 TCID50/ml of PRRSV strain IA 97-7895. 
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All pigs were necropsied at two weeks post challenge and serum was collected for PRRSV 
IDEXX ELISA, fluorescent focus neutralization (FFN), and qRT-PCR. Bronchial alveolar 
lavage (BAL) fluid was collected for qRT-PCR and deep cervical lymph nodes were 
collected and weighed. A section from each lung lobe was placed in formalin for 
histopathology. 
Experiment 2 
Experiment 2 involved six grnups of six pigs. Three week old pigs were randomly 
assigned to treatment groups, blocking for weight and sex. Table 3.2 displays the design for 
Experiment 2. 
Table 3.2: Experiment 2 Design 
Group Number Treatment 
1 Negative Control 
2 CCA 
3 CVA 
4 CV A/Neuraminidase 
5 CV AIPN GaseF 
6 CVA/N/P 
Number of Pigs 
6 
6 
6 
6 
6 
6 
Group 1 was the negative control group, Group 2 the positive control group that received 
CCA, Group3 received CV A, Group 4 received CV A treated with neuraminidase 
(CV A/Neuraminidase), Group 5 received CVA treated with PNGase F (CV A/PNGaseF) and 
Group 6 received CVA treated with neuraminidase and PNGase F (CV A/NIP). Crude viral 
antigen was prepared from PRRS strain IA 97-7895. Pigs in groups 2-6 were vaccinated 
three times with respective vaccines at two week intervals. Blood was collected from all pigs 
at two week intervals. Pigs in groups 2-6 were challenged IM with 2 milliliters of 5 X 105 
TCID50/ml PRRSV strain IA 97-7895 at 56 days post initial vaccination. Blood was 
collected from all pigs at 7 and 14 days post challenge. All pigs were necropsied at two 
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weeks post challenge and serum was collected for PRRSV IDEXX ELISA, FFN and qRT-
PCR. Bronchial alveolar lavage fluid was collected for qRT-PCR and a section from each 
lung lobe, deep cervical, tracheobronchial, iliac and external inguinal lymph nodes, tonsil and 
heart were collected and placed in formalin for histopathology. Lungs from all pigs were 
scored for estimated gross lung lesion involvement. All pigs were weighed at days 0, 28, 56 
and 72 days post initial vaccination. 
Experiment 3 
Experiment 3 involved six groups of six pigs. Three week old pigs were randomized 
into treatment groups, blocking for weight, and randomly placed into 4 different rooms with 
at least one treatment group represented in each room. Table 3.3 displays the design for 
Experiment 3. 
Table 3.3: Experiment 3 Design 
Group Number Treatment 
1 Negative Control 
2 CCA 
3 IA CVA 
4 IA CVA/N/P 
5 SNGCVA 
6 PRRomiSe® 
Number of Pigs 
6 
6 
6 
6 
6 
6 
Group 1 was the negative control group, Group 2 the positive control group that received 
CCA, Group 3 received PRRSV strain IA 97-7895 CVA (IA CVA), Group 4 received IA 
CVA treated with Neuraminidase and PNGase F (IA CV A/NIP), Group 5 received PRRSV 
strain SNG CVA (SNG CVA) and Group 6 received Intervet's commercial killed vaccine 
PRRomiSe®. Groups 2-6 were vaccinated three times at two week intervals with respective 
vaccines. Blood was collected from all pigs at two week intervals post initial vaccination and 
at 7 and 14 days post challenge. Pigs in groups 2-6 were intranasally challenged with two 
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milliliters of 3.97 X 104 TCID5o/ml PRRSV strain MN 184 at 56 days post initial 
vaccination. All pigs were necropsied at 14 days post challenge and serum was collected for 
PRRS IDEXX ELISA, FFN and qRT-PCR. Bronchial alveolar lavage fluid was collected for 
qRT-PCR and a section from each lung lobe, deep cervical, tracheobronchial, iliac and 
external inguinal lymph nodes, tonsil and heart were collected and placed in formalin for 
histopathology. Lungs from all pigs were scored for estimated gross lung lesion 
involvement. All pigs were weighed at the beginning and end of the experiment. 
During the experiment pigs began to have IDEXX ELISA SIP ratios prior to 
challenge. To ensure that the pigs were truly free from virus, qRT-PCR was run on all 
ELISA positive serum. At 42 days post initial inoculation (DPI), a negative control pig in a 
room was found to be ELISA positive. Subsequent qRT-PCR confirmed the presence of 
PRRSV in the room. All pigs were bled and qRT-PCR was used to confirm that the 
remaining rooms were still PRRS negative. The pigs in the contaminated room were 
removed and the experiment continued with continual qRT-PCR and ELISA monitoring of 
the remaining pigs. Table 3.4 displays number of pigs in each treatment after the 
contaminated room was removed from the experiment. 
Table 3.4: Experiment 3 Design 
Group Number Treatment 
1 Negative Control 
2 CCA 
3 IA CVA 
4 IA CVA/N/P 
5 SNGCVA 
6 PRRomiSe® 
Number of Pigs 
4 
4 
5 
5 
5 
4 
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Challenge PRRSV Strains 
The challenge PRRSV strain IA 97-7895 was used in Experiments 1 and 2; PRRSV 
strain MN 184 was used in Experiment 3. Table 3.5 presents the amino acid sequence 
present on GP5 in the region of the neutralizing epitope. A neutralizing epitope is present on 
GP5 comprising amino acids residues 37 to 45 95 . 
Table 3.5: PRRSV Amino Acid Sequence and Glycosylation Pattern of the 
Neutralizing Epitope Region of GP5 
PRRSV Strain GP5 Amino Acids 32 - 60* Glycan Position# 
SNG NSNSGSHLQ LIYNLTLCEL NGTDWLKDKF 44, 51 
IA 97-7895 NSNSSSHLQ LIYNLTLCEL NGTDWLKDKF 34, 44, 51 
* - N-linked glycosylation sites are found at amino acid sequences containing asparagine (N) 
- any amino acid except proline - serine (S) or threonine (T) and represented by underlined 
amino acids 
# - Glycan position represents the amino acid position ofN and is bolded 
Serology 
Serum assayed by IDEXX ELISA for antibodies to PRRSV was performed by the 
Iowa State University Veterinary Diagnostic Laboratory. Fluorescent focus neutralization 
was performed by the South Dakota State University Animal Disease Research and 
Diagnostic Laboratory. 
Real-Time Quantitative Reverse Transcriptase Polymerase Chain Reaction 
(qRT-PCR) 
Sera collected post challenge and from pigs with positive IDEXX ELISA results prior 
to challenge were assayed by qRT-PCR (Tetracore) using a Bio-Rad iCycler iQ. Viral RNA 
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was extracted using the Qiagen Virus Spin Kit. A 102 base pair in-vitro transcript was used 
as the standards at 101, 103, and 105 copies/uL to generate a standard curve. To each tube of 
Tetracore US-PRRSV master mix (16 reactions per tube), 36 uL of enzyme mix 1 was added. 
Four and one-halfuL of enzyme 2 was then added to each tube of master mix. Briefly, 
master mix was vortexed and 21 uL was aliquoted into each well of PCR plates. Four uL of 
extracted material was added to each respective well. The cycling conditions were as 
follows: 1) RT step: 52°C for 1800 seconds 2) enzyme activation step: 95°C for 900 seconds, 
3) 3-step PCR: 40 cycles (changed from Tetracore's recommended 50 cycles) at 94°C for 30 
seconds, 61 °C for 60 seconds, and 72°C for 60 seconds). 
Bronchial Alveolar Lavage 
Bronchial alveolar lavage was collected at the time of necropsy 76• Lungs were 
removed from the carcass and the left half of the lungs were severed from the trachea at the 
level of the left mainstem bronchus. Modified Eagle's Medium (MEM) containing 0.5 
mg/ml gentamicin was used to lavage the lungs. Fifty milliliters ofMEM was pipetted into 
the mainstem bronchus, aspirated and redispensed three times prior to collection. This step 
was repeated 3 times until 50 ml of BAL fluid was obtained per pig. The 50 ml of BAL fluid 
was thoroughly mixed and dispensed into three, 1 ml aliquots and stored at -80°C. 
Gross Lung Lesion Scoring 
Macroscopic lung lesions were blindly recorded at necropsy. Lesions were given a 
score to estimate the percentage of lung affected by pneumonia 45 . Each lung lobe was given 
a number to represent the approximate volume in relation to the entire lung. Ten points, five 
dorsal and five ventral, were assigned to each of the following: right cranial (anterior) lobe, 
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right middle lobe, cranial portion of the left cranial lobe and caudal portion of the left cranial 
lobe. Five points was assigned to the accessory lobe. Fifteen points were assigned to the 
dorsal portion of each caudal lobe and 12.5 points were assigned to the ventral portion of 
each caudal lobe. A total of 100 points was possible to estimate the percentage of grossly 
visible pneumonia. 
Histopathology 
Histopathology was performed on tissues taken from each pig at necropsy. The 
following tissues were sampled: lung - one section from each lung lobe, tonsil, heart, and 
lymph nodes - deep cervical, tracheobronchial, iliac and external inguinal. Tissue sections 
were blindly scored and lung sections were given and overall score for the extent of 
interstitial pneumonia present 47. Interstitial pneumonia was characterized by type 2 
pneumocyte hypertrophy and hyperplasia, septal infiltration with mononuclear cells and 
increased amount of necrotic alveolar exudate. Lung scores designate the following: 0 - No 
lesions, 1 - mild multifocal interstitial pneumonia (IP), 2 - mild diffuse IP, 3 - moderate 
multifocal IP, 4 - moderate diffuse IP, 5 - severe multifocal IP and 6 - severe diffuse IP. 
Lymph Node Scoring 
In Experiment 1, deep cervical and sternal lymph nodes were to be obtained from 
pigs at necropsy and weighed. Sternal lymph nodes were not consistently found and in some 
cases deep cervical lymph nodes were not found. For Experiments 2 and 3 lymph nodes 
were collected and evaluated for increased size only. Deep cervical, tracheobronchial, iliac 
and superficial inguinal lymph nodes of each pig were blindly evaluated for size. A 
representative from each lymph node was evaluated and scored as 0 = normal, 1 = lX normal 
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size, 2 = 2X normal size or 3 = 3X normal size. Lymph node sizes from each pig were 
averaged and then the group average was obtained. 
Weights 
In Experiments 2 and 3, pigs were weighed at the beginning of the trial and at 
necropsy. Mean treatment group weights at necropsy and mean group average daily gain 
was evaluated in each experiment. 
Viral Titration 
Viral titration was performed on all qRT-PCR positive serum at 14 days post 
challenge (DPC) and on bronchial alveolar lavage obtained at necropsy. Viral titrations were 
started by inoculating 200 uL of MARC-145 cells into each well of a 96-well plate. Plates 
were incubated for two days at 37°C with 5% CO2. After the incubation, wells were 
examined for the start of monolayer formation. Ten-fold serial dilutions of each serum 
sample were made by placing 100 uL of serum into 900 uL of DMEM. Fifty uL of each 
dilution was then added each respective well. Figure 3.1 displays the organization of each 96 
well plate. 
Two dilutions were made for each sample and a duplicate of each dilution was made. 
Duplicate wells were also allowed for positive and negative controls on each plate. Positive 
control dilutions and plating was performed prior to sample dilutions and plating to minimize 
the risk of contamination. Plates were then incubated at 3 7°C with 5% CO2 for three days. 
At the end of three days, all wells on each plate were fixed by adding 200 uL of a 70% 
acetone, 30% methanol solution. After 15 minutes the fixative/cell media solution was 
removed from the mono layer and an additional 200 uL of the fixative solution was placed 
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into each well for another 15 minutes. The fixative was then poured of and the plates were 
allowed to dry for 15 minutes. Next, 60 uL of FITC labeled SDOW-17 at a 1 :250 dilution 
was pipetted into each well. The plates were then incubated at 37°C with 5% CO2 for 45 
minutes. Each well on each plate was then washed with 200 uL of lX PBS. Each well was 
washed three times. The plates were patted dry and observed with microscope using the 1 OX 
objective with the aid of a fluorescent filter. The tissue culture infectious dose 50 per 
milliliter (TCID50/ml) for each sample was calculated using the Reed/Muench calculation 15. 
The serum virus titration assay has a sensitivity of 5* 102 TCID50/mL. Therefore, 
samples that did not have a minimum titer of 5 * 102 TCID50/mL were assigned a titer of< 
5*102 TCID50/mL. 
Figure 3.1: 96 well plate setup for viral titration 
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Viral titration for BAL samples was performed using a different protocol 53. Ten-fold 
serial dilutions of BAL fluid were made; 100 uL of BAL was diluted into 900 uL ofDMEM 
containing 2% FBS, 50 ug/ml gentamicin and 2.5 ug/ml Fungizone (lnvitrogen Corporation, 
Grand Island NY). Four replicates of each dilution were plated, and the plates were 
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incubated at 37°C with 5% CO2 for 8 days. After 8 days, each well was examined for CPE 
and TCID50/ml was calculated using the Reed-Muench calculation 15 . 
The BAL virus titration assay has a sensitivity of 2.5 * 102 TC!D50/mL. Therefore, 
samples that did not have a minimum titer of 2.5* 102 TC!D50/mL were assigned a titer of< 
2.5*102 TCIDso/mL. 
Statistical Analysis 
Statistical analysis was performed using JMP Statistical Software (SAS Institute Inc.). 
Nonparametric analysis using the Wilcoxon I Kruskal-Wall is test was performed to detect 
significant differences (p<0.05) between group means at each time point. Significant 
differences were further evaluated using pairwise Wilcoxon tests to determine which groups 
were significantly different (p<0.05 unless otherwise noted). 
Experiment 1 
Serology 
PRRS IDEXX ELISA 
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Chapter 4. Results 
Pigs in all groups remained negative by IDE.XX ELISA (SIP ratio <0.4) prior to 
challenge with the exception of two pigs in Group 2. The SIP ratios of sera from these two 
pigs in Group 2 were 4.525 and 2.688 at 56 days post inoculation (DPI) and 2.292 and 1.319 
at 42 DPI. All pigs seroconverted by 7 days post challenge (DPC) and the average SIP ratios 
for each group throughout the experiment are presented in Table 4.1 and Figure 4.1. At 56 
DPI and 63 DPI, the average S/P ratios for Group 2 and Group 3 were significantly different 
from Group 1. At 56 DPI and 63 DPI, the average S/P ratio for Group 2 was significantly 
different from Group 4. Positive SIP ratios at 42 and 56 DPI indicate that those respective 
pigs developed an immune response prior to exposure to PRRSV. PRRS IDE.XX ELISA 
results indicate the presence of antibody to N protein. 
Table 4.1: Experiment 1 Mean PRRS IDEXX ELISA SIP Ratios 
Group Number 0 days 21 days 42 days 
1 0.027 (0.018)* 0.027 (0.024) 0.020 (0.015) 
2 0.045 (0.047) 0.030 (0.017) 0.615 (0.972) 
3 0.022 (0.010) 0.041 (0.028) 0.052 (0.045) 
4 0.043 (0.037) 0.023 (0.019) 0.025 (0.045) 
56 days 
0.000 (0.000) 
1.336 (1.860t 
0.219 (0.384? 
0.028 (0.036) 
63 days 
0.379 (0.372) 
3.405 (0.269t 
2.274 (1.410) 
1.470 (1.211) 
70 days 
2.406 (1.149) 
5.040 (0.779) 
3.427 (1.612) 
3.374 (1.770) 
Results are represented as the mean group ELISA SIP ratios. Positive ELISA SIP ratios are ~0.4. Pigs in each group were vaccinated with respective 
vaccines at 0, 21 and 42 days. All pigs in all groups were challenged with PRRSV strain IA 97-7895 at 56 days. Group I = crude cellular antigen, Group 2 
= crude viral antigen, Group 3 = crude viral antigen bound to lectin, Group 4 = crude viral antigen bound to lectin and treated with PNGase F. 
* - Standard deviation (SD) for each mean is represented in parentheses • - significantly different from Groups I and 4 b - significantly different from 
Group I c - significantly different from Groups I and 4. 
41 
Figure 4.1: Experiment 1 Seroconversion detected by PRRSV IDEXX ELISA 
Results are represented as the average group SIP ratios. Positive ELISA SIP ratios are 2:0.4. Pigs in 
each group were vaccinated with respective vaccines at 0, 21 and 42 days. All pigs in all groups were 
challenged with PRRSV strain IA 97-7895 at 56 days. Group 1 = crude cellular antigen, Group 2 = crude viral 
antigen, Group 3 = crude viral antigen bound to lectin, Group 4 = crude viral antigen bound to lectin and treated 
with PNGase F. At 56 and 63 DPI, Groups 2 and 3 were significantly different from Group I. At 56 and 63 
DPI, Group 2 was significantly different from Group 4. 
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The serological response of pigs as measured by fluorescent focus neutralization 
(FFN) is summarized in Figures 4.2 and 4.3. Fluorescent focus neutralization data indicates 
the level of neutralizing antibody present. Sera collected from pigs on 0, 7 and 14 days post 
challenge were assayed by the FFN test using PRRSV strains IA 97-7895 and SD 23983. 
Figure 4.2 represents average serum FFN titers using PRRSV strain IA 97-7895 and Figure 
4.3 represents average serum FFN titers using PRRSV strain SD 23983. 
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Figure 4.2 : Experiment 1 Average Serum FFN Titer at 7 and 14 DPC 
with PRRSV strain IA 97-7895 
Results represent the inverse of the average serum FFN titer for each group. Vertical lines above each 
bar represent the standard deviation for each mean. Positive FFN titers are 2: 4. Pigs in each group were 
vaccinated with respective vaccines at 0, 21 and 42 days. All pigs in all groups were challenged with PRRSV 
strain IA 97-7895 at 56 days. Group 1 = crude cellular antigen, Group 2 = crude viral antigen, Group 3 = crude 
viral antigen bound to lectin, Group 4 = crude viral antigen bound to lectin and treated with PNGase F. At 7 
DPC, Group 2 was significantly different from all other groups and Group 3 was significantly different from 
Groups 1 and 4. At 14 DPC, Group 2 was significantly different from Groups I and 4 (p <0.05) and Group 3 
(p<0.1) 
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All sera collected on 0 DPC were negative, (<1 :4) (data not shown). Average serum 
FFN titers using PRRSV strain IA 97-7895 were the highest in Group 2. The average serum 
titer from pigs in Group 2 was significantly different from all other treatment groups and 
Group 3 was significantly different from Group 1 and Group 4 at 7 DPC. At 14 DPC, Group 
2 was significantly different from Group 1 and Group 4, p < 0.05, and from Group 3, p < 0.1. 
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Figure 4.3 : Experiment 1 Average Serum FFN Titer at 7 and 14 DPC 
with PRRSV Strain SD 23983 
Results represent the inverse of the average serum FFN titer for each group. Vertical lines above each 
bar represent the standard deviation for each mean. Positive FFN titers are 2': 4. Pigs in each group were 
vaccinated with respective vaccines at 0, 21 and 42 days. All pigs in all groups were challenged with PRRSV 
strain IA 97-7895 at 56 days. Group I = crude cellular antigen, Group 2 = crude viral antigen, Group 3 = crude 
viral antigen bound to lectin, Group 4 = crude viral antigen bound to Iectin and treated with PNGase F. At 7 
DPC, Group 2 was significantly different from Group I. 
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The average titer for Group 2 is significantly different (p < 0.05) from Group 1 at 7 
DPC. The results in Figure 4.3 indicate that there was cross-reacting serum neutralizing 
antibody between PRRSV strain IA 97-7895, the challenge strain, and PRRSV strain SD 
23983 with the highest average titers being found in Group 2. 
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The mean and standard deviation of serum FFN titers for each group at 7 and 14 DPC 
are presented in Table 4.2. 
Table 4.2: Experiment 1 Average Serum FFN Titers 
DPC 7 14 
Group Number IA 97-7895 IA 97-7895 
1 2.33 (0.82)* 12.67(11. 15) 
2 18.67 (10.93) 26.67 (8.26) 
3 8.00 (4.38) 16.00 (8.76) 
4 3.67 (2.34) 9.33 (5.47) 
7 
SD 23983 
4.33 (5.89) 
10.00 (4.38) 
8.00 (5.32) 
5.33 (4.46) 
14 
SD 23983 
8.67 (1.97) 
12.00 (4.90) 
11.33 (4.38) 
8.33 (2.07) 
Results represent the average serum inverse FFN titer for each group. Positive FFN titers are ~ 4 . Pigs in each 
group were vaccinated with respective vaccines at 0, 21 and 42 days. All pigs in all groups were challenged 
with PRRSV strain IA 97-7895 at 56 days. Group 1 = crude cellular antigen, Group 2 = crude viral antigen, 
Group 3 = crude viral antigen bound to lectin, Group 4 = crude viral antigen bound to Iectin and treated with 
PNGase F. At 7 DPC with PRRSV strain IA 97-7895, Group 2 was significantly different from all other groups 
and Group 3 was significantly different from Groups 1 and 4. At 7 DPC with PRRSV strain SD 23983, Group 
2 was significantly different from Group 1. At 14 DPC with PRRS strain IA 97-7895, Group 2 was 
significantly different from Groups 1 and 4 (p <0.05) and Group 3 (p<0. l) 
* - SD represented in parentheses 
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Real Time Quantitative Reverse Transcriptase Polymerase Chain Reaction 
(qRT-PCR) 
Serum collected from pigs at 7 and 14 DPC was evaluated by qRT-PCR (Figure 4.4). 
Figure 4.4: Experiment 1 Serum qRT-PCR Results 
Results represent the average number of viral copies per milliliter in serum for each group. Vertical 
lines above each bar represent the standard deviation for each mean. Pigs in each group were vaccinated with 
respective vaccines at 0, 21 and 42 days . All pigs in all groups were challenged with PRRSV strain IA 97-7895 
at 56 days. Group 1 = crude cellular antigen, Group 2 = crude viral antigen, Group 3 = crude viral antigen 
bound to lectin, Group 4 = crude viral antigen bound to lectin and treated with PNGase F. No significant 
difference was present at either time point. 
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In three of the four treatment groups only one pig was viremic at 14 DPC. Group 1 
had one pig with 2.58* 103 viral copies/mL, Group 2 had one pig with 2.64* 105 copies/mL, 
and Group 4 had one pig with 6.8* 102 copies/mL. Within treatment Group 3, three pigs had 
detectable virus with values greater than 103 viral copies/mL, one pig had detectable virus 
with a value greater than 105 viral copies/mL and the remaining two pigs did not have 
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detectable virus in their serum. No statistically significant differences in viral copies/mL 
were present at either time point. Data presented in Figure 4.4 demonstrates that there was a 
reduction in viremia 14 DPC. 
Bronchial alveolar lavage fluid was collected at necropsy and evaluated using qRT-
PCR (Table 4.3). In Experiment 1 consistent amounts of BAL fluid were not added to each 
lung, therefore quantitative data should only be interpreted as positive or negative. 
Table 4.3 : Experiment 1 BAL qRT-PCR 
Group Number Average Viral Copies/mL 
1 2.71E+04 (3.23E+04)* 
2 5.10E+03 (4.29E+03) 
3 5.47E+03 (5.04E+03) 
4 1.64E+03 (l.42E+03) 
No. of Positive Pigs 
6 of6 
6 of6 
6 of6 
6 of6 
Results represent the average number of viral copies per milliliter in BAL for each group. Pigs in each group 
were vaccinated with respective vaccines at 0, 21 and 42 days. All pigs in all groups were challenged with 
PRRSV strain IA 97-7895 at 56 days. Group I = crude cellular antigen, Group 2 = crude viral antigen, Group 3 
= crude viral antigen bound to lectin, Group 4 = crude viral antigen bound to lectin and treated with PNGase F. 
* - SD represented in parentheses 
Data in Table 4.3 demonstrates that although viremia was reduced in treatment 
groups 1, 2 and 4, virus was still present within the lungs. 
Viral Titration 
Virus was only found in one pig in Group 3 at a titer of5*102 TCID50/mL. Virus was 
not detected in the remaining positive pigs by viral titration and those pigs had viral titers of 
< 5*102 TCIDso/mL. 
Viral titration was also performed on BAL fluid. Table 4.4 presents the mean viral 
titer per group and the number of pigs with positive titers. 
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Table 4.4: Experiment 1 BAL Viral Titration 
Group Number Average TCIDso/mL * 
1 1.16E+03 (7.48E+02) 1 
No. of Positive Pigs# 
2 1.15E+03 (9.05E+02) 
3 7.92E+03 (1.16E+04) 
4 8.34E+03 (1.13E+04) 
5 of6 
6 of6 
6 of6 
4 of6 
Results represent the average number ofTCID5o/mL in BAL for each group. Serum viral titrations were 
performed on all pigs with positive qRT-PCR results at 14 DPC. Pigs in each group were vaccinated with 
respective vaccines at 0, 21 and 42 days. All pigs in all groups were challenged with PRRSV strain IA 97-7895 
at 56 days. Group 1 = crude cellular antigen, Group 2 = crude viral antigen, Group 3 = crude viral antigen 
bound to Iectin, Group 4 = crude viral antigen bound to lectin and treated with PNGase F. 
1 
- SD represented in parentheses 
* - Mean derived from sample with a determinable titer 
# - Includes pigs with CPE in one well yielding an undeterminable titer 
Lymph Node Scoring 
The average lymph node weights are presented in Table 4.5. 
Table 4.5: Experiment 1 Lymph Node Weights 
Group Number Pigs Sampled Average Wt. in Grams 
1 n=6 13.590 (2.331)* 
2 n=5 11.939 (2.028) 
3 n=6 11.332 (1.365) 
4 n=4 13.070 (3.545) 
Range 
9.897-15.955 
9.902-14.550 
9.591-12.504 
9.742-16.145 
Results represent the average lymph node weight for each group. Deep cervical and sternal lymph nodes were 
collected and weighted at necropsy. Pigs in each group were vaccinated with respective vaccines at 0, 21 and 
42 days. All pigs in all groups were challenged with PRRSV strain IA 97-7895 at 56 days. Group 1 = crude 
cellular antigen, Group 2 = crude viral antigen, Group 3 = crude viral antigen bound to lectin, Group 4 = crude 
viral antigen bound to lectin and treated with PNGase F. No significant difference was present between groups 
* - SD represented in parentheses 
Sternal lymph nodes were not consistently found and only deep cervical lymph nodes 
were weighed. In some instances deep cervical lymph nodes were also not found. The 
number of lymph nodes that were weighed per group is also presented Table 4.5. There was 
not a statistically significant difference in lymph node weight between treatment groups. 
Experiment 2 
Serology 
IDEXXELISA 
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Average S/P ratios for sera collected from pigs in each group are presented in Table 
4.6 and Figure 4.5 . Two pigs, pig 66 and pig 72, in Group 3 had positive S/P ratios of 2.519 
and 0.559 respectively at 42 DPI. At 56 DPI, only pig 66 had a positive SIP ratio of 2.154 
while the SIP ratio for pig 72 had fallen to 0.107. Average serum ELISA S/P ratios from 
Groups 2 to 6 were significantly different from Group 1 at 7 and 14 DPC; however 
significant differences were not present between means from Groups 2 to 6. 
Table 4.6: Experiment 2 PRRS IDEXX ELISA Mean SIP Ratios 
Group 0 days 14 days 28 days 42 days 56 days 63 days 70 days No. 
1 0.003 (0.007)* 0.012 (0.019) 0.000 (0.000) 0.021 (0.016) 0.014 (0.015) 0.017 (0.014) 0.037 (0.021) 
2 0.003 (0.008) 0.003 (0.006) 0.000 (0.000) 0.024 (0.016) 0.039 (0.033) 1.343 (0.418) 1.539 (0.375) 
3 0.007 (0.017) 0.000 (0.000) 0.020 (0.046) 0.574 (0.974) 0.397 (0.861) 2.577 (0.734) 2.385 (0.598) 
4 0.004 (0.009) 0.000 (0.000) 0.000 (0.000) 0.035 (0.018) 0.041 (0.018) 2.230 (0.301) 2.333 (0.253) 
5 0.000 (0.000) 0.002 (0.003) 0.004 (0.009) 0.074 (0.067) 0.027 (0.013) 1.750 (0.380) 1.884 (0.373) 
6 0.009 (0.015) 0.000 (0.000) 0.060 (0.124) 0.061 (0.035) 0.057 (0.056) 1. 725 (0. 707) 1.825 (0.948) 
Results are represented as the mean group SIP ratios. Pigs in each group were vaccinated with respective vaccines at 0, 14 and 28 days . All pigs in all 
groups were challenged with PRRSV strain IA 97-7895 at 56 days. Group l = negative control, Group 2 = crude cellular antigen, Group 3 = crude viral 
antigen, Group 4 = crude viral antigen treated with neuraminidase, Group 5 = crude viral antigen treated with PNGaseF, Group 6 = crude viral antigen 
treated with both neuraminidase and PNGase F. Average serum ELISA S/P ratios for Groups 2 to 6 were significantly different from Group l at 7 and 14 
DPC. * - SD is represented in parentheses 
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Figure 4.5: Experiment 2 Seroconversion Detected by PRRSV IDEXX ELISA 
Results are represented as the mean group S/P ratios. Pigs in each group were vaccinated with 
respective vaccines at 0, 14 and 28 days. All pigs in all groups were challenged with PRRSV strain IA 97-7895 
at 56 days. Group I = negative control, Group 2 = crude cellular antigen, Group 3 = crude viral antigen, Group 
4 = crude viral antigen treated with neuraminidase, Group 5 = crude viral antigen treated with PNGaseF, Group 
6 = crude viral antigen treated with both neuraminidase and PNGase F. Average serum ELISA SIP ratios for 
Groups 2 to 6 were significantly different from Group I at 7 and 14 DPC. 
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The serologic response of pigs as measured by FFN is presented in Figure 4.6. Serum 
collected from pigs on O and 14 DPC was assayed by the FFN test with both PRRSV strains 
IA 97-7895 and SD 23983 strains. All serum samples from all pigs were negative (titer< 
1 :4) on FFN testing for both strains at O DPC. 
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Figure 4.6: Experiment 2 Average Serum FFN Titers with PRRSV Strains 
IA 97-7895 and SD 23983 at 14 DPC 
Results represent the inverse of the average serum FFN titer for each group. Vertical lines above each 
bar represent the standard deviation for each mean. Pigs in each group were vaccinated with respective 
vaccines at 0, 14 and 28 days. All pigs in all groups were challenged with PRRSV strain IA 97-7895 at 56 
days. Group I = negative control, Group 2 = crude cellular antigen, Group 3 = crude viral antigen, Group 4 = 
crude viral antigen treated with neuraminidase, Group 5 = crude viral antigen treated with PNGaseF, Group 6 = 
crude viral antigen treated with both neuraminidase and PNGase F. For PRRSV strain IA 97-7895, Group 6 
was significantly different from Groups I and 5. For PRRSV strain SD 23983 no significant difference was 
present. 
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Table 4.7: Experiment 2 Average Serum FFN Titers 
DPC 14 14 
Group Number IA - 977895 SD 23983 
1 2.33 (0.82)* 2.00 (0.00) 
2 9.67 (6.98) 2.67 (1.03) 
3 15.00 (24.12) 4.33 (5.72) 
4 3.67 (2.34) 2.67 (1.03) 
5 3.00 (2.45) 3.00 (2.45) 
6 14.67 (9.35) 4.33 (2.94) 
Results represent the inverse of the average serum FFN titer for each group. Pigs in each group were vaccinated 
with respective vaccines at 0, 14 and 28 days. All pigs in all groups were challenged with PRRSV strain IA 97-
7895 at 56 days. Group I = negative control, Group 2 = crude cellular antigen, Group 3 = crude viral antigen, 
Group 4 = crude viral antigen treated with neuraminidase, Group 5 = crude viral antigen treated with PNGaseF, 
Group 6 = crude viral antigen treated with both neuraminidase and PNGase F. For PRRSV strain IA 97-7895, 
Group 6 was significantly different from Groups I and 5. For PRRSV strain SD 23983 no significant difference 
was present. * - SD represented in parentheses 
Group 6 was significantly different from Group 1 and Group 5 for titers obtained 
using PRRSV strain IA 97-7895. No significant differences were found in the FFN data 
using PRRSV strain SD 23983 data. Table 4.7 presents the mean and standard deviation for 
FFN titers at 14 DPC. 
The FFN data demonstrates the presence of heterologous protection, particularly in 
Groups 3 and 6. The heterologous response observed in Experiment 2 was weaker, on 
average than the response observed in Experiment 1. Additionally, some pigs failed to 
develop a neutralizing antibody immune response. 
Real Time Quantitative Reverse Transcriptase Polymerase Chain Reaction 
(qRT-PCR) 
Quantitative RT-PCR was performed on serum from each pig at 7 and 14 DPC. 
Results are presented in Figure 4.7. No virus was detectable in the serum of pigs from Group 
1. At 7 DPC, average viral loads for Group 2 to 6 were significantly different from Group 1. 
No significant difference was present between challenged groups at 7 DPC. At 14 DPC, 
Groups 2, 4 and 5 had viral loads significantly different from Group 1. No significant 
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differences were present between challenged groups at 14 DPC. Table 4.6 presents mean 
level of viremia and the number of viremic pigs present within each group at 14 DPC. 
Figure 4.7: Experiment 2 Serum qRT-PCR Results 
Results represent the average number of viral copies per milliliter in serum for each group. Vertical 
lines above each bar represent the standard deviation for each mean. Pigs in each group were vaccinated with 
respective vaccines at 0, 14 and 28 days. All pigs in all groups were challenged with PRRSV strain IA 97-7895 
at 56 days. Group I (negative control) was qRT-PCR negative (data not shown). Group 2 = crude cellular 
antigen, Group 3 = crude viral antigen, Group 4 = crude viral antigen treated with neuraminidase, Group 5 = 
crude viral antigen treated with PNGaseF, Group 6 = crude viral antigen treated with both neuraminidase and 
PNGase F. At 7 DPC, Groups 2 to 6 were significantly different from Group I. At I 4 DPC, Groups 2,4 and 5 
were significantly different from Group I . 
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Table 4.8: Experiment 2 Average Serum Viral Load at 14 DPC 
Group Number 
2 
3 
4 
5 
6 
Average Viral Load 
7.88E+03 (l .08E+04)* 
7.45E+03 (1. 18E+04) 
6.68E+04 (1.1 IE+05) 
2.62E+04 (3.58E+04) 
9.36E+03 (1.92E+04) 
Number of Positive Pigs 
6 of6 
2 of6 
5 of6 
6 of6 
3 of6 
Results represent the average number of viral copies per milliliter in serum for each group. Pigs in each group 
were vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in all groups were challenged with 
PRRSV strain IA 97-7895 at 56 days. Group I = negative control, Group 2 = crude cellular antigen, Group 3 = 
crude viral antigen, Group 4 = crude viral antigen treated with neuraminidase, Group 5 = crude viral antigen 
treated with PNGaseF, Group 6 = crude viral antigen treated with both neuraminidase and PNGase F. At 7 
DPC, Groups 2 to 6 were significantly different from Group 1. At 14 DPC, Groups 2,4 and 5 were significantly 
different from Group I . * - SD represented in parentheses 
Quantitative RT-PCR values from BAL are presented in Table 4.9. In Experiment 2 
consistent amounts of BAL fluid were not added to each lung, therefore quantitative data 
should only be interpreted as positive or negative. This data demonstrates that although 
some pigs were not viremic, PRRSV was still present in the lungs. 
Table 4.9: Experiment 2 BAL qRT-PCR 
Group Number Average Viral Copies/mL 
1 0.00E+00 (0.00E+00)* 
2 8.32E+05 (8.13E+05) 
3 2.18E+05 (1.86E+05) 
4 3.13E+05 (l.49E+05) 
5 3.85E+05 (3.52E+05) 
6 l.98E+05 (3.01E+05) 
No. of Positive Pigs 
0 of6 
6 of6 
6 of6 
6 of6 
6 of6 
6 of6 
Results represent the average number of viral copies per milliliter in BAL for each group. Pigs in each group 
were vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in all groups were challenged with 
PRRSV strain IA 97-7895 at 56 days. Group I = negative control, Group 2 = crude cellular antigen, Group 3 = 
crude viral antigen, Group 4 = crude viral antigen treated with neuraminidase, Group 5 = crude viral antigen 
treated with PNGaseF, Group 6 = crude viral antigen treated with both neuraminidase and PNGase F. * - SD 
represented in parentheses 
Viral Titration 
Serum viral titrations were performed on all pigs with positive qRT-PCR results at 14 
DPC. The number of pigs per group with positive serum qRT-PCR results is listed in Table 
4.8. Viral titers were determined for two of the five positive pigs in Group 4. Two pigs in 
Group 4 had titers of 5* 102 and 5* 103 TCIDso/mL while the remaining three pigs had titers 
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<5 * 102 TCID50/mL. All other pigs with positive qRT-PCR results had titers of <5 * 102 
TCIDso/mL. Four of the six pigs in Group 5 had virus present in one well of the lowest 
dilution and one of the three qRT-PCR positive pigs in Group 6 had virus present in one well 
at the lowest dilution. This definitively demonstrates that these animals were viremic, 
however, it is possible that any animal with a titer of< 5* 102 TCID50/mL could have a low 
level of viremia. 
Virus titration was also performed on BAL fluid. As with qRT-PCR on BAL, viral 
titration results should only be interpreted as positive or negative. Table 4.10 presents the 
mean viral titer per group and the number of positive pigs per group. 
Table 4.10: Experiment 2 BAL Viral Titration 
Group Number Average TCID5o/mL Number of Positive Pigs# 
2 l.22E+04 (l.06E+04)* 6 of 6 
3 l.11E+04 (2.39E+04) 5 of 6 
4 l.88E+04 (3.09E+04) 6 of 6 
5 2.46E+04 (3.35E+04) 6 of 6 
6 l.25E+06 (l.77E+06) 2 of 6 
Results represent the average TCID5o/mL in BAL for each group. Lavage fluid from all pigs in Group 1 was 
qRT-PCR negative and titration was not performed. Pigs in each group were vaccinated with respective 
vaccines at 0, 14 and 28 days. All pigs in all groups were challenged with PRRSV strain IA 97-7895 at 56 
days. Group 2 = crude cellular antigen, Group 3 = crude viral antigen, Group 4 = crude viral antigen treated 
with neuraminidase, Group 5 = crude viral antigen treated with PNGaseF, Group 6 = crude viral antigen treated 
with both neuraminidase and PNGase F. * - SD represented in parentheses # - Number of pigs with a titer 2'. 
2.50E+02 
Gross Lung Lesion Scores 
Mean gross lung lesion scores are presented in Table 4.11. The scores represent the 
average percentage of lung grossly affected by pneumonia. Gross lung lesion scores were 
not performed in Experiment 1 due to the method of euthanasia. In Experiment 1 pig were 
euthanized by electrocution. Electrocution made the determination of gross percentage of 
lung affected by pneumonia impossible due to artifact lesions. In Experiment 2, pigs were 
euthanized with the aid of sedation followed by an intravenous overdose of sodium 
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pentobarbital; allowing for gross lung lesion scoring. The average gross lesion score for 
Group 1 was significantly different from all other groups. No significant difference was 
present between Groups 2 to 6. 
Table 4.11: Experiment 2 Gross Lung Lesion Scores 
Group Number Average Gross Lesion Score 
1 0.50 (0.50)* 
2 14.08 (15.18) 
3 22.42 (20.16) 
4 19.08 (15.45) 
5 33.33 (22.21) 
6 10.58 (8.73) 
Range 
0-1 
3-44 
6-58 
0-41 
1-62 
1-24 
Results represent the average gross lung lesion score for each group. Pigs in each group were vaccinated with 
respective vaccines at 0, 14 and 28 days. All pigs in all groups were challenged with PRRSV strain IA 97-7895 
at 56 days. Group 1 = negative control, Group 2 = crude cellular antigen, Group 3 = crude viral antigen, Group 
4 = crude viral antigen treated with neuraminidase, Group 5 = crude viral antigen treated with PNGaseF, Group 
6 = crude viral antigen treated with both neuraminidase and PNGase F. Groups 2 to 6 were significantly 
different from Group 1. * - SD represented in parentheses 
Lymph Node Scoring 
Due to the difficulties in consistently finding sternal and deep cervical lymph nodes 
in Experiment 1 and the lack of significant difference between weights a new method of 
lymph node evaluation was utilized. In Experiment 2 four different lymph nodes were 
located and blindly scored for increase in size. The deep cervical, tracheobronchial, iliac and 
superficial inguinal lymph nodes of each pig were scored. Table 4.12 presents the average 
lymph node enlargement by group. Statistically there is not a significant difference between 
groups. 
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Table 4.12: Experiment 2 Lymph Node Enlargement 
Group Number 
1 
2 
3 
4 
5 
6 
Mean Times Normal 
0.00 (0.00)* 
2.13 (0.38) 
1.92 (0.61) 
1.75 (0.71) 
2.25 (0.57) 
1.92 (0.34) 
Range 
0-0 
1.5-3 
1.25 - 3 
1 - 1.75 
1.25 - 1.75 
1.25 - 2.25 
Results represent the average lymph node enlargement for each group. Deep cervical, tracheobronchial, iliac 
and superficial inguinal lymph nodes were evaluated. Pigs in each group were vaccinated with respective 
vaccines at 0, 14 and 28 days. All pigs in all groups were challenged with PRRSV strain IA 97-7895 at 56 
days. Group I = negative control, Group 2 = crude cellular antigen, Group 3 = crude viral antigen, Group 4 = 
crude viral antigen treated with neuraminidase, Group 5 = crude viral antigen treated with PNGaseF, Group 6 = 
crude viral antigen treated with both neuraminidase and PNGase F. No significant difference was present 
between groups. * - SD represented in parentheses 
Weight 
Mean group weights at necropsy, 14 DPC, and mean group average daily gain is 
presented in Table 4.13. There is not a significant difference between mean group weights or 
mean group average daily gain. 
Table 4.13: Experiment 2 Average Group Weights at 14 DPC 
and Mean Group Average Daily Gain 
Group No. Average Weight 14 DPC Average Daily Gain 
1 
2 
3 
4 
5 
6 
158.00 (19.43) 1.84 (0.23) 
153.17 (16.63) 1.77 (0.21) 
142.83 (7.65) 1.63 (0.12) 
144.17 ( 6.08) 1.65 (0.09) 
142.50 (6.41) 1.63(0.11) 
140.20 (15.17) 1.58 (0.20) 
Pigs in each group were weighed at the beginning of the experiment and at necropsy. Pigs in each group were 
vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in all groups were challenged with PRRSV 
strain IA 97-7895 at 56 days. Group I = negative control, Group 2 = crude cellular antigen, Group 3 = crude 
viral antigen, Group 4 = crude viral antigen treated with neuraminidase, Group 5 = crude viral antigen treated 
with PNGaseF, Group 6 = crude viral antigen treated with both neuraminidase and PNGase F. No significant 
difference was present between groups. * - SD represented in parentheses 
Histopathology 
Histopathology data is presented in Table 4.14. There is not a statistically significant 
difference between average interstitial pneumonia scores between groups. In Group 3, two 
pigs had scores ofless than 3, indicating only mild interstitial pneumonia. In Group 4, three 
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pigs had interstitial pneumonia scores of less than 3. One pig received a score of O due to 
atelectasis and the other two pigs received scores of 1 and 2. In Groups 4 and 5, two pigs 
received scores of 2. Lymphohistiocytic myocarditis is a histopathology characteristic 
commonly seen in PRRS infections. 
Table 4.14: Experiment 2 Histopathology Results 
Group No. 
1 
2 
3 
4 
5 
6 
Average IP Score 1 
1 
4.5 
3.2 
2.3 
4.2 
2.8 
Range 
0-2 
3-6 
1-5 
0-5 
3-6 
2-4 
No. IP Score 2:: 4 
0 of6 
5 of6 
3 of6 
1 of 6 
4 of6 
1 of 6 
No. Heart Lesions2 
0 of6 
3 of6 
2 of6 
2 of6 
2 of6 
0 of6 
Pigs in each group were vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in all groups were 
challenged with PRRSV strain IA 97-7895 at 56 days. Group 1 = negative control, Group 2 = crude cellular 
antigen, Group 3 = crude viral antigen, Group 4 = crude viral antigen treated with neuraminidase, Group 5 = 
crude viral antigen treated with PNGaseF, Group 6 = crude viral antigen treated with both neuraminidase and 
PNGase F. No significant difference in average interstitial pneumonia scores was present. 
1 
- IP = Interstitial Pneumonia scored on a scale of O - 6. 
2 
- Heart lesions consisting of mild, moderate or severe lymphohistiocytic myocarditis. 
Summary of Individual Pig Data 
Table 4.15 presents individual pig data from FFN, IDEXX ELISA, qRT-PCR, gross 
lung lesion scores and histopathology scores at 14 DPC. 
Table 4.15: Experiment 2 Individual Pig Data Summary for 14 DPC 
Pigs in each group were vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in all groups were challenged with PRRSV strain IA 97-7895 at 
56 days. Group I = negative control, Group 2 = crude cellular antigen, Group 3 = crude viral antigen, Group 4 = crude viral antigen treated with 
neuraminidase, Group 5 = crude viral antigen treated with PNGaseF, Group 6 = crude viral antigen treated with both neuraminidase and PNGase F. 
Experiment 2 Inverse FFN Titer IDEXX Serum BAL Lung Score Histopath Pig ID SD 23983 IA 97-7895 ELISA qRT-PCR qRT-PCR IP Score 
41 2 4 0.012 0.00E+00 0.00E+00 1 0 
56 2 2 0.032 
...... 
0.00E+00 0.00E+00 1 1 
§< 60 2 2 0.060 0.00E+00 0.00E+00 0 1 
0 65 ND* ND ND ND ND ND ND ... 0 
71 2 2 0.057 0.00E+00 0.00E+00 0 1 
52 2 2 0.026 0.00E+00 0.00E+00 0.5 2 
44 4 16 1.224 4.58E+03 2.93E+05 11.5 3 
45 4 16 0.958 2.81E+03 l.70E+05 11.5 5 N 
§< 46 2 4 1.813 3.59E+03 2.11E+05 3 4 
0 49 2 4 1.709 6.05E+03 2.11E+06 44 4 ... 0 
54 2 16 1.937 6.85E+02 l.56E+06 11 6 
75 2 2 1.591 2.96E+04 6.55E+05 3.5 5 
59 2 4 1.265 0.00E+00 l.92E+05 6 3 
63 16 64 3.000 0.00E+00 3.42E+05 58 5 (") 
§< 66 2 4 2.440 l.87E+04 7.35E+04 32 4 
0 67 2 8 2.339 0.00E+00 l.59E+05 22 1 ... 0 
72 2 2 2.746 0.00E+00 2.02E+04 9.5 2 
73 2 8 2.519 2.60E+04 5.25E+05 7 4 
* - Not determined, pig 65 was euthamzed pnor to the completion of the study 
V, 
'-0 
Table 4.15 Continued 
Pigs in each group were vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in all groups were challenged with PRRSV strain IA 97-7895 at 
56 days. Group 1 = negative control, Group 2 = crude cellular antigen, Group 3 = crude viral antigen, Group 4 = crude viral antigen treated with 
neuraminidase, Group 5 = crude viral antigen treated with PNGaseF, Group 6 = crude viral antigen treated with both neuraminidase and PNGase F. 
Experiment 2 Inverse FFN Titer IDEXX Serum BAL Lung Score Histopath Pig ID SD 23983 IA 97-7895 ELISA qRT-PCR qRT-PCR IP Score 
42 4 4 2.113 2.70E+05 3.86E+05 41 5 
47 4 4 2.570 3.42E+03 4.50E+05 21 3 
"" §< 50 2 8 2.009 0.00E+00 2.40E+05 2.5 0 
2 57 2 2 2.662 3.69E+03 2.03E+05 25 2 d 
62 2 2 2.282 0.00E+00 l.14E+05 25 1 
70 2 2 2.363 1.24E+05 4.87E+05 0 3 
39 2 2 2.082 9.70E+04 7.20E+05 36 4 
40 2 2 1.365 8.95E+03 5.90E+04 20 3 V) 
§< 53 2 2 2.167 2.59E+03 6.50E+05 28 3 
0 58 8 8 1.570 2.84E+04 7.40E+05 53 6 1-4 d 
61 2 2 2.329 l.47E+04 l.19E+05 1 4 
68 2 2 1.789 5.90E+03 2.06E+04 62 5 
43 2 8 1.580 0.00E+00 7.20E+05 15 4 
48 2 16 1.719 0.00E+00 1.67E+04 7 2 \0 
§< 55 8 8 2.199 3.00E+03 1.83E+04 1 2 
0 64 4 16 1.550 0.00E+O0 6.65E+03 2.5 3 1-4 d 
69 8 8 3.395 4.89E+03 1.59E+04 14 3 
74 2 32 0.504 4.83E+04 4.l 1E+05 24 3 
Experiment 3 
Serology 
IDEXXELISA 
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IDEXX ELISA data is presented in Table 4.16 and Figure 4.8. One of five pigs in 
Group 3 developed an antibody response, SIP ratio of 1.078, at 28 DPI. Three of the five 
pigs in Group 5 developed antibody responses at 28 DPI, SIP ratios of 2.035, 0.991 and 
0.465. At 42 DPI, three pigs in Group 3 had developed antibody responses, S/P ratios of 
2.702, 1.741 and 0.937, while in Group 5 four pigs had positive ELISA S/P ratios of2.525, 
2.478, 2.348 and 2.035. At 56 DPI, all pigs in Group 3 and Group 5 had become ELISA 
positive. At 28 DPI, the Group 5 average SIP ratio was significantly different, p < 0.05, from 
all other treatment groups with the exception of Group 3 where significant difference was 
present at p < 0.10. Also at 28 DPI, Group 3 was significantly different from Groups 1, 2 
and 4. At 42 DPI, Group 5 was significantly different from all treatment groups with the 
exception of Group 3. Group 3 was significantly different from Groups 1 and 6 at 42 DPI. 
At 56, 63 and 70 DPI, Group 3 and Group 5 were significantly different from the other four 
treatment groups. 
Table 4.16: Experiment 3 PRRS IDEXX ELISA Mean SIP Ratios 
Group 0 days 14 days 28 days 42 days 56 days 63 days 70 days No. 
1 0.000 (0.000)* 0.035 (0.019) 0.030 (0.025) 0.032 (0.024) 0.019 (0.014) 0.005 (0.011) 0.023 (0.027) 
2 0.020 (0.041) 0.016 (0.010) 0.021 (0.018) 0.180(0.112) 0.024 (0.041) 0.018 (0.016) 1.436 (0.308) 
3 0.000 (0.000) 0.020 (0.017) 0.280 (0.448) 1.102 (1.135) 1.388 (1.000) 1.293 (0.539) 3.409 (0.349) 
4 0.000 (0.000) 0.020 (0.011) 0.003 (0.006) 0.109 (0.123) 0.080 (0.048) 0.101 (0.099) 1.633 (0.891) 
5 0.002 (0.004) 0.048 (0.071) 0.772 (0.779) 1.888 (1.049) 2.310 (0.980) 1.660 (0.538) 3.722 (0.168) 
6 0.000 (0.000) 0.015 (0.020) 0.046 (0.024) 0.030 (0.018) 0.024 (0.017) 0.011 (0.013) 1.738 (0.460) 
Results are represented as the mean group SIP ratios. Pigs in each group were vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in Groups 
2 - 6 were challenged with PRRSV strain MN 184 at 56 days. Group I = negative control, Group 2 = crude cellular antigen, Group 3 = PRRSV strain IA 
97-7895 crude viral antigen, Group 4 = PRRS strain IA 97-7895 crude viral antigen treated with neuraminidase and PNGase F, Group 5 = PRRSV strain 
SNG crude viral antigen, Group 6 = PRRomiSe®. At 28 DPI, Group 5 was significantly different from Groups 1, 2, 4 and 6 (p<0.05) and was significantly 
different from Group 3 (p<0.10). At 28 DPI, Group 3 was significantly different from Groups l , 2 and 4. At 42 DPI, Group 5 was significantly different 
from Group 1, 2, 4, and 6 and Group 3 was significantly different from Groups 1 and 6. At 56, 63 and 70 DPI, Groups 3 and 5 were significantly different 
from the other four groups. * - SD represented in parentheses 
0\ 
N 
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Figure 4.8: Experiment 3 Seroconversion detected by PRRSV IDEXX ELISA 
Results are represented as the mean group S/P ratios. Pigs in each group were vaccinated with 
respective vaccines at 0, 14 and 28 days. All pigs in Groups 2 - 6 were challenged with PRRSV strain MN 184 
at 56 days. Group I = negative control, Group 2 = crude cellular antigen, Group 3 = PRRSV strain IA 97-7895 
crude viral antigen, Group 4 = PRRS strain IA 97-7895 crude viral antigen treated with neuraminidase and 
PNGase F, Group 5 = PRRSV strain SNG crude viral antigen, Group 6 = PRRomiSe®. At 28 DPI, Group 5 was 
significantly different from Groups 1, 2, 4 and 6 (p<0.05) and was significantly different from Group 3 
(p<0. l 0). At 28 DPI, Group 3 was significantly different from Groups 1, 2 and 4. At 42 DPI, Group 5 was 
significantly different from Group 1, 2, 4, and 6 and Group 3 was significantly different from Groups 1 and 6. 
At 56, 63 and 70 DPI, Groups 3 and 5 were significantly different from the other four groups. 
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Serum FFN titers are presented in Figure 4.9 and Tables 4.17 and 4.18. The FFN 
assay was performed on all sera from pigs that developed an ELISA response prior to and 
after challenge. Figure 4.9 presents data from day 14 post challenge for PRRSV strains SNG 
and MN 184. Four pigs, two pigs from Group 3 and two pigs from Group 5 had FFN titers 
prior to challenge with PRRSV strain MN 184 (Table 4.18). There was not a significant 
difference between group titers at 14 DPC for either strain of PRRSV. 
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Figure 4.9: Experiment 3 Average Serum FFN Titer - PRRS Strains SNG and MN 184 
Results represent the inverse of the average serum FFN titer for each group. Vertical lines above each 
bar represent the standard deviation for each mean. Pigs in each group were vaccinated with respective 
vaccines at 0, 14 and 28 days. All pigs in Groups 2 - 6 were challenged with PRRSV strain MN I 84 at 56 days. 
Group 1 = negative control, Group 2 = crude cellular antigen, Group 3 = PRRSV strain IA 97-7895 crude viral 
antigen, Group 4 = PRRS strain IA 97-7895 crude viral antigen treated with neuraminidase and PNGase F, 
Group 5 = PRRSV strain SNG crude viral antigen, Group 6 = PRRomiSe®. No significant differences were 
present. 
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Table 4.17: Experiment 3 Average Serum FFN Titers 
DPC 14 14 
Group Number SNG MN 184 
1 2 (0.00)* 2.5 (1.00) 
2 2.5 (1.00) 3 (1.15) 
3 2.4 (0.89) 3.2 (2.68) 
4 4.4 (2.19) 4 (0.00) 
5 11.2 (13.01) 4.4 (3.29) 
6 5 (3.46) 3.5 (3.00) 
Results represent the inverse of the average serum FFN titer for each group. Pigs in each group were vaccinated 
with respective vaccines at 0, 14 and 28 days. All pigs in Groups 2 - 6 were challenged with PRRSV strain MN 
184 at 56 days. Group 1 = negative control, Group 2 = crude cellular antigen, Group 3 = PRRSV strain IA 97-
7895 crude viral antigen, Group 4 = PRRS strain IA 97-7895 crude viral antigen treated with neuraminidase and 
PNGase F, Group 5 = PRRSV strain SNG crude viral antigen, Group 6 = PRRomiSe®. No significant 
differences were present. * - SD represented in parentheses 
Table 4.18: Experiment 3 Positive FFN Titers Prior to Challenge 
DPI 42 42 56 56 
PRRS Strain SNG MN 184 SNG MN 184 
Group 3 - Pig 76 4 2 8 8 
Group 3 - Pig 99 ND* ND 2 32 
Group 5 - Pig 13 2 8 2 4 
Group 5 - Pig 98 ND ND 16 2 
Results represent the inverse of the serum FFN titer. Pigs in each group were vaccinated with respective 
vaccines at 0, 14 and 28 days. All pigs in Groups 3 and 5 were challenged with PRRSV strain MN 184 at 56 
days. Group 3 = PRRSV strain IA 97-7895 crude viral antigen, Group 5 = PRRSV strain SNG crude viral 
antigen. * - Not determined (ND) - Assay not run on sera from this day 
Real Time Quantitative Reverse Transcriptase Polymerase Chain Reaction 
(qRT-PCR) 
Quantitative RT-PCR was performed at 7 and 14 DPC and results are presented in 
Figure 4.10. At 7 DPC, the Group 1 was significantly different from all other treatment 
groups. At 14 DPC, Group 1 was significantly different, p < 0.05, all other treatment groups 
with the exception of Group 3 where significance was at p < 0.10. At 14 DPC, Group 4 is 
significantly different, p < 0.10, from Group 2 and Group 5. Table 4.19 presents mean level 
ofviremia and the number ofviremic pigs present within each group at 14 DPC. 
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Figure 4.10: Experiment 3 Serum qRT-PCR Results 
Results represent the average number of viral copies per milliliter in serum for each group. Vertical 
lines above each bar represent the standard deviation for each mean. No virus was detected in Group 1 (data 
not shown). Pigs in each group were vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in 
Groups 2 - 6 were challenged with PRRSV strain MN 184 at 56 days. Group 1 = negative control, Group 2 = 
crude cellular antigen, Group 3 = PRRSV strain IA 97-7895 crude viral antigen, Group 4 = PRRS strain IA 97-
7895 crude viral antigen treated with neuraminidase and PNGase F, Group 5 = PRRSV strain SNG crude viral 
antigen, Group 6 = PRRomiSe®. Group 1 was significantly different from Groups 2 to 6 at 7 and 14 DPC with 
the exception of Group 3 at 14 DPC were significance was p<0.10. At 14 DPC, Group 4 was significantly 
different from Groups 2 and 5. 
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Table 4.19: Experiment 3 Average Serum Viral Load at 14 DPC 
Group Number Average Viral Load Number of Positive Pigs 
I 0.00E+00 (0.00E+00)* 0 of 4 
2 8.15E+05 (1.53E+06) 4 of 4 
3 6.72E+05 (1.02E+06) 3 of 5 
4 3.37E+04 (6.08E+04) 4 of 5 
5 4.94E+05 (4.50E+05) 4 of 5 
6 2.49E+03 (4.64E+05) 4 of 4 
Results represent the average number of viral copies per milliliter in serum for each group. Pigs in each group 
were vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in Groups 2 - 6 were challenged with 
PRRSV strain MN 184 at 56 days. Group 1 = negative control, Group 2 = crude cellular antigen, Group 3 = 
PRRSV strain IA 97-7895 crude viral antigen, Group 4 = PRRS strain IA 97-7895 crude viral antigen treated 
with neuraminidase and PNGase F, Group 5 = PRRSV strain SNG crude viral antigen, Group 6 = PRRomiSe®. 
Group 1 was significantly different from Groups 2 to 6 at 7 and 14 DPC with the exception of Group 3 at 14 
DPC were significance was p<0.10. At 14 DPC, Group 4 was significantly different from Groups 2 and 5. 
* - SD represented in parentheses 
Quantitative RT-PCR values from BAL are presented in Table 4.20. In Experiment 3 
consistent amounts of BAL fluid were added to and recovered from each lung in effort to 
quantify the amount of virus present in the BAL. 
Table 4.20: Experiment 3 BAL qRT-PCR 
Group Number Average Viral Copies/mL 
1 0.00E+00 (0.00E+00)* 
2 6.96E+06 (3.70E+06) 
3 3.29E+07 (6.50E+07) 
4 9.53E+06 (1.55E+07) 
5 1.32E+07 (1.32E+07) 
6 1.03E+07 (8.55E+06) 
No. of Positive Pigs 
0 of4 
4 of4 
5 of5 
5 of5 
4 of5# 
4 of4 
Pigs in each group were vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in Groups 2 - 6 
were challenged with PRRSV strain MN 184 at 56 days. Group 1 = negative control, Group 2 = crude cellular 
antigen, Group 3 = PRRSV strain IA 97-7895 crude viral antigen, Group 4 = PRRS strain IA 97-7895 crude 
viral antigen treated with neuraminidase and PNGase F, Group 5 = PRRSV strain SNG crude viral antigen, 
Group 6 = PRRomiSe®. Group 1 is significantly different from Groups 2 to 6. * - SD represented in 
parentheses # - BAL not obtained from one pig in Group 5 
Viral Titration 
Serum viral titrations were performed on all pigs with positive qRT-PCR results at 14 
DPC. The number of pigs per group with positive qRT-PCR results is listed in Table 4.19. 
Table 4.21 presents the number of pigs in each group that had titers and the number of pigs 
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that had virus present in only one well. Pigs with virus present in only one well were 
assigned a titer of <5* 102 TCID50/mL although they can be considered to be viremic. 
Table 4.21: Experiment 3 Serum Viral Titration 
Group Number No. Pigs w/ Titer No. Pigs w/ Virus in 1 Well 
2 2 2 
3 2 1 
4 1 0 
5 2 1 
6 1 1 
Pigs in Group 1 were negative for virus by qRT-PCR and titration was not performed. Pigs in each group were 
vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in Groups 2 - 6 were challenged with 
PRRSV strain MN 184 at 56 days. Group 2 = crude cellular antigen, Group 3 = PRRSV strain IA 97-7895 
crude viral antigen, Group 4 = PRRS strain IA 97-7895 crude viral antigen treated with neuraminidase and 
PNGase F, Group 5 = PRRSV strain SNG crude viral antigen, Group 6 = PRRomiSe®. 
Table 4.22 presents serum viral titers from pigs in each group that had a determinable 
titer and the qRT-PCR values for each pig. 
Table 4.22: Experiment 3 Individual Serum Viral Titers 
and Serum qRT-PCR Results 
Group I Pig Number 
Group 2 - Pig 2 
Group 2 - Pig 24 
Group 3 - Pig 84 
Group 3 - Pig 99 
Group 4 - Pig 93 
Group 5 - Pig 78 
Group 5 - Pig 80 
Group 6 - Pig 100 
TCIDso/mL 
l.06E+04 
5.00E+02 
l.06E+05 
5.00E+03 
2.28E+04 
l.06E+05 
5.00E+02 
5.00E+02 
Viral Copies/mL 
3.15E+06 
3.18E+04 
2.38E+06 
9.00E+05 
l.42E+05 
8.25E+05 
8.75E+05 
3.91E+04 
Pigs in each group were vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in Groups 2 - 6 
were challenged with PRRSV strain MN 184 at 56 days. Group 2 = crude cellular antigen, Group 3 = PRRSV 
strain IA 97-7895 crude viral antigen, Group 4 = PRRS strain IA 97-7895 crude viral antigen treated with 
neuraminidase and PNGase F, Group 5 = PRRSV strain SNG crude viral antigen, Group 6 = PRRomiSe®. 
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Virus titration was also performed on BAL fluid. Table 4.23 presents the mean viral 
titer per group and the number of positive pigs per group. 
Table 4.23: Experiment 3 BAL Viral Titration 
Group Number Average TCIDso/mL Number of Positive Pigs 
2 
3 
4 
5 
6 
l.52E+04 (2.55E+04)* 
1.95E+04 (2.08E+04) 
l.77E+03 (l.01E+03) 
7.79E+04 (l.15E+05) 
1.49E+04 (2.57E+04) 
4 of4 
5 of5 
5 of 5 
4 of5# 
4 of4 
Pigs in Group 1 were negative for virus by qRT-PCR and titration was not performed. Pigs in each group were 
vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in Groups 2 - 6 were challenged with 
PRRSV strain MN 184 at 56 days. Group 2 = crude cellular antigen, Group 3 = PRRSV strain IA 97-7895 
crude viral antigen, Group 4 = PRRS strain IA 97-7895 crude viral antigen treated with neuraminidase and 
PNGase F, Group 5 = PRRSV strain SNG crude viral antigen, Group 6 = PRRomiSe®. Group 4 was 
significantly different from Groups 3 and 5. * - SD represent in parentheses. # - BAL not obtained from one 
pig in Group 5 
Gross Lung Lesion Scores 
Mean gross lung lesion scores are presented in Table 4.24. The scores represent the 
average percentage of lung grossly affected by pneumonia. Group 1 was significantly 
different from all other groups and no significant difference was observed between Groups 2 
to 6. 
Table 4.24: Experiment 2 Gross Lung Lesion Scores 
Group Number 
1 
2 
3 
4 
5 
6 
Average Gross Lesion Score 
0 (0.0)* 
29 (16.9) 
29 (25.3) 
21 (20.6) 
48 (23.5) 
41 (29.1) 
Range 
0-0 
6-43 
3-67 
5-57 
13 -65 
7-72 
Pigs in each group were vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in Groups 2 - 6 
were challenged with PRRSV strain MN 184 at 56 days. Group 1 = negative control, Group 2 = crude cellular 
antigen, Group 3 = PRRSV strain IA 97-7895 crude viral antigen, Group 4 = PRRS strain IA 97-7895 crude 
viral antigen treated with neuraminidase and PNGase F, Group 5 = PRRSV strain SNG crude viral antigen, 
Group 6 = PRRomiSe®. Group 1 was significantly different from Groups 2 to 6. * - SD represented in 
parentheses 
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Lymph Node Scoring 
Table 4.25 presents the average lymph node enlargement by group. No significant 
difference was present between groups. 
Table 4.25: Experiment 3 Lymph Node Enlargement 
Group Number 
1 
2 
3 
4 
5 
6 
Mean Times Normal 
0 (0.00)* 
1.25 (0.96) 
0.74 (0.86) 
0.84 (0.78) 
1 (0.58) 
1 (0.58) 
Range 
0-0 
0-2 
0-2 
0-1.5 
0.5 - 1.5 
0.5- 1.5 
Deep cervical, tracheobronchial, iliac and superficial inguinal lymph nodes were blindly scored from each pig. 
Pigs in each group were vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in Groups 2 - 6 
were challenged with PRRSV strain MN 184 at 56 days. Group I = negative control, Group 2 = crude cellular 
antigen, Group 3 = PRRSV strain IA 97-7895 crude viral antigen, Group 4 = PRRS strain IA 97-7895 crude 
viral antigen treated with neuraminidase and PNGase F, Group 5 = PRRSV strain SNG crude viral antigen, 
Group 6 = PRRomiSe®. No significant differences were present. * - SD represented in parentheses 
Weight 
Mean group weights at necropsy, 14 DPC, and mean group average daily gain is 
presented in Table 4.26. Weights were not obtained for pigs in Group 1. Group 1 was 
housed in a facility where a scale was unavailable. There is not a significant difference 
between mean group weights or mean group average daily gain. 
Table 4.26: Experiment 3 Average Group Weights at 14 DPC 
and Mean Group Average Daily Gain 
Group No.# Average Weight 14 DPC Average Daily Gain 
2 104.75 (8.10)* 1.16 (0.09)* 
3 102(19.72) 1.11(0.27) 
4 101.8 (10.33) 1.11 (0.13) 
5 111. 75 (7 .59) 1.23 (0.08) 
6 109.75 (15.71) 1.23 (0.19) 
# - Weights from pigs in Group 1 were not obtained. Pigs were weighed at the beginning of the experiment and 
at necropsy (14 DPC). Pigs in each group were vaccinated with respective vaccines at 0, 14 and 28 days. All 
pigs in Groups 2 - 6 were challenged with PRRSV strain MN 184 at 56 days. Group I = negative control, 
Group 2 = crude cellular antigen, Group 3 = PRRSV strain IA 97-7895 crude viral antigen, Group 4 = PRRS 
strain IA 97-7895 crude viral antigen treated with neuraminidase and PNGase F, Group 5 = PRRSV strain SNG 
crude viral antigen, Group 6 = PRRomiSe®. No significant differences were present. * - SD represented in 
parentheses 
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Histopathology 
Histopathology data is presented in Table 4.27. There is not a statistically significant 
difference between average interstitial pneumonia scores between groups. The interstitial 
pneumonia scores are greater than the scores observed in Experiment 2, however direct 
comparisons cannot be made due to differing challenge PRRSV strains. 
Table 4.27: 
Group No. 
1 
2 
3 
4 
5 
6 
Experiment 3 Histopathology Results 
Average IP Score1 Range No. IP Score 2:: 4 
1.75 1-2 0of4 
5.5 5 - 6 4 of 4 
5 4-6 5 of 5 
4.4 4-6 5 of 5 
5.5 4 - 6 5 of 5 
4.25 3 - 6 2 of 4 
No. Heart Lesions2 
0 of4 
2 of4 
1 of 5 
1 of 5 
1 of 5 
1 of 4 
Pigs in each group were vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in Groups 2 - 6 
were challenged with PRRSV strain MN 184 at 56 days. Group 1 = negative control, Group 2 = crude cellular 
antigen, Group 3 = PRRSV strain IA 97-7895 crude viral antigen, Group 4 = PRRS strain IA 97-7895 crude 
viral antigen treated with neuraminidase and PNGase F, Group 5 = PRRSV strain SNG crude viral antigen, 
Group 6 = PRRomiSe®. No significant differences in interstitial pneumonia scores were present. 
1 
- IP = Interstitial Pneumonia scored on a scale of O - 6. 
2 
- Heart lesions consisting of mild, moderate or severe lymphohistiocytic myocarditis. 
Summary of Individual Pig Data 
Table 4.28 presents individual pig data from FFN, IDEXX ELISA, qRT-PCR, gross 
lung lesion scores and histopathology scores at 14 DPC. 
Table 4.28: Experiment 3 Individual Pig Data Summary for 14 DPC 
Pigs in each group were vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in Groups 2 - 6 were challenged with PRRSV strain MN 184 at 
56 days. Group I = negative control, Group 2 = crude cellular antigen, Group 3 = PRRSV strain IA 97-7895 crude viral antigen, Group 4 = PRRS strain IA 
97-7895 crude viral antigen treated with neuraminidase and PNGase F, Group 5 = PRRSV strain SNG crude viral antigen, Group 6 = PRRomiSe®. 
Experiment 3 Inverse FFN Titer IDEXX Serum BAL Lung Score Histopath 
Pig ID SNG MN 184 ELISA qRT-PCR qRT-PCR IP Score 
12 2 2 0.000 0.00E+00 0.00E+00 0 2 
-ff 86 2 4 0.038 0.00E+00 0.00E+00 0 2 
0 87 2 2 0.053 0.00E+00 0.00E+00 0 2 I-< 0 
97 2 2 0.000 0.00E+00 0.00E+00 0 1 
2 2 2 1.064 3.15E+06 1.08E+07 26 6 
N 
ff 24 2 4 1.711 3.18E+04 7.50E+06 6 5 
0 89 4 4 1.304 l.30E+05 7.80E+06 40 5 I-< 0 
94 2 2 1.666 9.80E+04 l.74E+06 43 6 
76 2 2 3.915 8.40E+04 2.37E+06 38 6 
~ 81 2 2 3.536 0.00E+00 3.31E+04 10 4 
ff 84 4 2 2.968 2.38E+06 l.49E+08 27 5 0 
I-< 
0 96 2 2 3.283 0.00E+00 4.83E+06 3 4 
99 2 8 3.343 9.00E+05 8.30E+06 67 6 
Table 4.28: Continued 
Pigs in each group were vaccinated with respective vaccines at 0, 14 and 28 days. All pigs in Groups 2 - 6 were challenged with PRRSV strain MN 184 at 
56 days. Group 1 = negative control, Group 2 = crude cellular antigen, Group 3 = PRRSV strain IA 97-7895 crude viral antigen, Group 4 = PRRS strain IA 
97-7895 crude viral antigen treated with neuraminidase and PNGase F, Group 5 = PRRSV strain SNG crude viral antigen, Group 6 = PRRomiSe®. 
Experiment 3 Inverse FFN Titer IDEXX Serum BAL Lung Score Histopath 
Pig ID SNG MN 184 ELISA qRT-PCR qRT-PCR IP Score 
8 4 4 1.879 0.00E+00 2.27E+06 5 4 
'<t' 79 4 4 2.889 4.l 1E+03 7.10E+06 57 6 §< 91 2 4 1.764 9.60E+03 7.20E+05 12 4 0 
I-< 
0 92 8 4 0.511 1.26E+04 7.25E+05 14 4 
93 4 4 1.121 1.42E+05 3.69E+07 17 4 
13 4 8 3.749 7.65E+05 3.21E+07 56 6 
Ir) 14 16 2 3.632 0.00E+00 ND* ND 6 §< 78 2 2 3.809 8.25E+05 l.03E+07 57 6 0 
I-< 
0 80 2 8 3.930 8.75E+05 9.35E+06 65 6 
98 32 2 3.491 6.10E+03 l.21E+06 13 4 
15 2 2 1.323 
\0 
5.15E+03 2.84E+06 7 3 
§< 82 2 8 1.366 9.45E+05 8.20E+06 28 5 
0 95 8 2 2.047 8.00E+03 2.26E+07 72 3 I-< 0 
100 8 2 2.217 3.91E+04 7.45E+06 57 6 
* - Not determined, pig 14 died one day prior to the completion of the study 
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Chapter 5. Discussion and Conclusions 
The object_ives of this research were to determine if killed PRRSV vaccines could 
induce a serum neutralizing antibody response to PRRSV and to determine if killed PRRSV 
vaccines could provide protection from infection and clinical disease caused by PRRSV. 
In Experiment 1, two pigs from Group 2 developed an immune response, as measured 
by IDEXX ELISA, prior to challenge. Both of these pigs were viremic at 7 DPC, while only 
one pig was viremic at 14 DPC. Neither pig developed a neutralizing immune response prior 
to challenge. Pigs in Group 2 developed a significantly higher homologous neutralizing 
antibody response than pigs in the other groups (p < 0.01) and a higher heterologous 
neutralizing antibody response than pigs in other treatment groups. Only one pig in Group 1 
was viremic at 14 DPC; however virus was detected in BAL from all pigs in all groups by 
qRT-PCR at 14 DPC. The level ofviremia, determined by qRT-PCR, was decreased in all 
groups at 14 DPC with Group 4 having the largest decrease in viremia. 
Due to pigs in Group 2 developing an immune response prior to challenge and a 
significant neutralizing antibody response post challenge, the decision was made to abandon 
the use of lectin for binding CV A. The CV A preparation was not adequately binding to the 
lectin, therefore, the process of enzymatically treating CV A bound to lectin was modified in 
subsequent experiments to enzymatically treating only CV A. The CV A was passed through 
columns containing either neuraminidase or PNGase Fin an effort to remove glycans. 
Vaccines prepared in this manner were evaluated in Experiment 2. 
In Experiment 2, two pigs from Group 3 developed an immune response, measured 
by IDEXX ELISA, prior to challenge. Neutralizing antibody responses were not observed 
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prior to challenge and the magnitude of the neutralizing antibody response was decreased in 
both homologous and heterologous FFN assays. Viremia was again decreased for all groups 
at 14 DPC. Groups 3 and 6 had two and three viremic pigs at 14 DPC, respectively. 
However, virus was present in all BAL samples from pigs in Groups 2 - 6. Additionally, 
gross lung lesion and histopathology scores indicated the presence of disease due to PRRSV. 
The individual pig summary data presented in Table 4.14 indicates that there is not a clear 
correlation between IDEXX ELISA SIP ratio, serum FFN titer, serum and BAL viral load, 
gross lung lesion score and histopathology interstitial pneumonia score. Analysis of these 
findings led to the hypothesis that the antigenic load of each vaccine was too low to induce a 
neutralizing and protective immune response. Therefore, in Experiment 3 total protein 
concentration of each vaccine was dramatically increased. 
In Experiment 3, a new CVA preparation was used from PRRSV strain SNG. The 
SNG strain of PRRSV is a natural N-glycan mutant and is lacking glycosylation sites near 
the neutralizing epitope region, comprising amino acid residues 37 to 45, of GP5 (Table 3.5) 
95
. Work by Faaberg et al. 36 and Kaniewski et al. 54 has demonstrated that live inoculation 
with PRRSV strain SNG rapidly induces a neutralizing antibody response. The best immune 
response had been observed with CVA preparations, thus, the CVA of PRRSV strain SNG 
was added as a treatment group. A treatment group receiving Intervet's commercial killed 
PRRSV vaccine was also added in an effort to directly compare experimental vaccine 
performance to commercial vaccine performance. 
In addition to increasing total protein concentrations of each vaccine, the challenge 
strain for Experiment 3 was changed to PRRSV strain MN 184. The IA 97-7895 PRRSV 
strain, used in Experiments 1 and 2, is an abortifacient strain that was isolated from a case of 
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atypical PRRSV in southeast Iowa 93 94 . To better evaluate protection from respiratory 
disease the MN 184 strain, which is known to be highly virulent and produce severe 
respiratory disease 53 , was used to challenge pigs in Groups 2 - 6. 
In Experiment 3 an immune response, as measured by IDEXX ELISA, was first 
detected at 28 DPI in Groups 3 and 5 and all pigs in these two groups had positive IDEXX 
ELISA SIP ratios prior to challenge. Neutralizing antibody was first detected in one pig from 
Group 3 and one pig from Group 5 at 42 DPI and two pigs from each group had neutralizing 
antibody titers prior to challenge. Despite the early induction of an immune response, most 
pigs in each group were viremic at 14 DPC and virus was present in the BAL of all pigs in 
Groups 2 - 6. Gross lung lesion and histopathology indicate that disease was present. The 
individual pig summary data presented in Table 4.26 indicates that there is not a clear 
correlation between IDEXX ELISA SIP ratio, serum FFN titer, serum and BAL viral load, 
gross lung lesion score and histopathology interstitial pneumonia score. 
Direct comparisons of prevention of infection and disease in Experiment 2 and 
Experiment 3 cannot be made due to differing challenge strains. However, the immune 
response developed prior to challenge can be compared. The immune response observed in 
Experiment 3 occurred earlier than the response seen in Experiment 2. Prior to challenge all 
pigs in the IA 97-7895 and SNG CVA group developed antibody to N protein and two pigs 
from each of these groups developed a neutralizing immune response. Thus, the objective to 
stimulate a neutralizing antibody response prior to challenge was partly successful. 
However, this immune response was not protective as demonstrated by qRT-PCR, gross lung 
lesion scores and histopathology interstitial pneumonia scores. The early immune response 
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can be attributed to the increase in total protein delivered in each vaccination; however, the 
amount of viral protein versus cellular protein was unknown. 
Yoon et al. 143 demonstrated that subneutralizing levels of antibody enhanced PRRSV 
replication. Pigs were given an intraperitoneal (IP) injection of normal swine serum or 
neutralizing antibody titers of :SI :2, 1 :4 and 1: 16 and evaluated for level of viremia post 
challenge. Evidence of antibody-dependent enhancement (ADE) of viral infection was 
monitored in serum harvested from each pig on the day of challenge. On the day of 
challenge ADE activity was not present in pigs that received IP neutralizing antibody with a 
titer of 1: 16. Additionally, pigs in this group had a significantly lower level of viremia and 
duration ofviremia. These results indicated that ADE can occur in presence of 
subneutralizing antibody with a titer between 1 :2 and 1 :4. Furthermore, western immunoblot 
analysis indicated that antibody to GP5 likely facilitated the ADE. Antibody-dependent 
enhancement of infection may have played a role in the outcome of Experiment 3. Pigs with 
neutralizing antibody present at the time of challenge did not have lower levels of viremia 
and showed signs of severe disease at 14 DPC. Additionally, some pigs in treatment groups 
2 - 6 had a low level of neutralizing antibody present at 14 DPC. The presence of 
neutralizing antibody did not decrease serum or BAL viral loads and did not prevent gross or 
microscopic lesions, suggesting that the low level neutralizing antibody may be facilitating 
ADE in these pigs as well. 
Lopez et al. 67 demonstrated that viremia could be prevented at the time of challenge 
in the presence of a neutralizing antibody titer of 1 :8 and that a titer of 1 :32 provides 
sterilizing immunity. These results suggest that a vaccine that could induce a neutralizing 
antibody response with a titer greater than 1 :32 could provide protection from PRRSV 
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infection. Vaccine preparations used in this research were not able to induce a neutralizing 
antibody response of this magnitude. A possible explanation for the lack of an adequate 
response lies in the vaccine preparation. The method used for CV A preparation was based 
on methods used to generate inactivated subunit vaccines for Pseudorabies virus 55 105 . In 
PRRSV infected cells, progeny virions accumulate in the endoplasmic reticulum of the 
infected cell and are released from the cell by exocytosis or cell lysis 140• It is possible that a 
large portion of the PRRSV protein was removed from vaccine preparation when the 
supernatant was removed following the initial centrifugation step. Thus, the pellet used for 
CVA preparation would contain mostly cellular proteins resulting in a total protein 
concentration consisting primarily of non-viral antigens. When the total protein 
concentration was increased an earlier immune response was observed. The immune 
response was primarily characterized by the presence of non-neutralizing and non-protective 
antibody to N protein. Further studies using purified viral protein derived from supernatant 
prepared from methods utilized in this research may stimulate a larger neutralizing immune 
response due to the presence of larger concentrations of PRRSV antigen. Also, the success 
of enzymatic degradation ofN-glycans may be increased if purified viral protein preparations 
are used. Purified viral protein preparations may provide further information on the 
immunopathogenesis of PRRSV isolates with varying degrees of GP5 glycosylation and 
provide further understanding of the role of GP5 glycosylation in PRRSV pathogenesis. 
Additionally, western immunoblot assays could be performed on serum from these 
studies to further characterize the antibody response to the CV A preparations. Western 
immunoblot assays would demonstrate to which viral proteins antibody was being produced. 
As DNA vaccines co-expressing GP5 and M protein have been shown to induce higher 
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neutralizing antibody titers; it would be of interest to determine whether neutralizing 
antibody specific to the GP5/M heterodimer was produced 51 . Furthermore, future killed 
vaccine preparations could be analyzed by western immunoblot assays for the presence of 
GP5/M heterodimer following inactivation. 
In summary, killed PRRSV vaccine preparations utilized in this research were able to 
stimulate an early non-protective immune response prior to challenge with live PRRSV. 
Further studies evaluating the immune response and protection from infection and disease 
with killed vaccines, derived from purified viral protein preparations enzymatically treated to 
remove N-glycans or from natural N-glycan mutants, could lead to further understanding of 
role of GP5 glycosylation in relation to the development of a neutralizing and protective 
immune response. 
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